<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK26468" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK26468/" /><meta name="ncbi_pagename" content="Ataxia-Telangiectasia - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Ataxia-Telangiectasia - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Ataxia-Telangiectasia" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2016/10/27" /><meta name="citation_author" content="Richard Gatti" /><meta name="citation_author" content="Susan Perlman" /><meta name="citation_pmid" content="20301790" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK26468/" /><meta name="citation_keywords" content="Louis-Bar Syndrome" /><meta name="citation_keywords" content="Serine-protein kinase ATM" /><meta name="citation_keywords" content="ATM" /><meta name="citation_keywords" content="Ataxia-Telangiectasia" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Ataxia-Telangiectasia" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Richard Gatti" /><meta name="DC.Contributor" content="Susan Perlman" /><meta name="DC.Date" content="2016/10/27" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK26468/" /><meta name="description" content="Classic ataxia-telangiectasia (A-T) is characterized by progressive cerebellar ataxia beginning between ages one and four years, oculomotor apraxia, choreoathetosis, telangiectasias of the conjunctivae, immunodeficiency, frequent infections, and an increased risk for malignancy, particularly leukemia and lymphoma. Individuals with A-T are unusually sensitive to ionizing radiation. Non-classic forms of A-T have included adult-onset A-T and A-T with early-onset dystonia." /><meta name="og:title" content="Ataxia-Telangiectasia" /><meta name="og:type" content="book" /><meta name="og:description" content="Classic ataxia-telangiectasia (A-T) is characterized by progressive cerebellar ataxia beginning between ages one and four years, oculomotor apraxia, choreoathetosis, telangiectasias of the conjunctivae, immunodeficiency, frequent infections, and an increased risk for malignancy, particularly leukemia and lymphoma. Individuals with A-T are unusually sensitive to ionizing radiation. Non-classic forms of A-T have included adult-onset A-T and A-T with early-onset dystonia." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK26468/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/ataxia-telangiectas/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK26468/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C10B2E0407CB100000000052901E0.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK26468_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK26468_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/aved/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ao2/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK26468_"><span class="title" itemprop="name">Ataxia-Telangiectasia</span></h1><p class="contrib-group"><span itemprop="author">Richard Gatti</span>, MD and <span itemprop="author">Susan Perlman</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK26468_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK26468_ai__"><div class="contrib half_rhythm"><span itemprop="author">Richard Gatti</span>, MD<div class="affiliation small">Departments of Pathology and Human Genetics<br />David Geffen School of Medicine at UCLA<br />Los Angeles, California<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.alcu.tendem@ittagr" class="oemail">ude.alcu.tendem@ittagr</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Susan Perlman</span>, MD<div class="affiliation small">Department of Neurology<br />David Geffen School of Medicine<br />UCLA Health System<br />Los Angeles, California<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.alcu.tendem@namlreps" class="oemail">ude.alcu.tendem@namlreps</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">March 19, 1999</span>; Last Update: <span itemprop="dateModified">October 27, 2016</span>.</p><p><em>Estimated reading time: 30 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="ataxia-telangiectas.Summary" itemprop="description"><h2 id="_ataxia-telangiectas_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Classic ataxia-telangiectasia (A-T) is characterized by progressive cerebellar ataxia beginning between ages one and four years, oculomotor apraxia, choreoathetosis, telangiectasias of the conjunctivae, immunodeficiency, frequent infections, and an increased risk for malignancy, particularly leukemia and lymphoma. Individuals with A-T are unusually sensitive to ionizing radiation. Non-classic forms of A-T have included adult-onset A-T and A-T with early-onset dystonia.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of A-T is suspected based on suggestive clinical and preliminary laboratory findings and &#x02013; in some instances &#x02013; neuroimaging and family history. The diagnosis is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> either by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> to document the presence of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> (<a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a>) <i>ATM</i> pathogenic variants or (when available) by immunoblotting to test for absent or reduced ATM protein.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i></p><ul><li class="half_rhythm"><div>Neurologic: supportive therapy and medications (when possible) as well as early and continued physical therapy to reduce the risk for contractures and scoliosis.</div></li><li class="half_rhythm"><div>Immunodeficiency: IVIG replacement therapy as needed for (a) frequent and severe infections and (b) low IgG levels.</div></li><li class="half_rhythm"><div>Pulmonary: multidisciplinary management that emphasizes monitoring of recurrent infection, pulmonary function, swallowing, nutrition, scoliosis, and immune function.</div></li><li class="half_rhythm"><div>Cancer: because of the increased <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of A-T cells, use of ionizing radiation and some chemotherapeutic agents requires careful monitoring.</div></li></ul><p><i>Prevention of secondary complications:</i> Gastrostomy tube feedings are occasionally needed to prevent pulmonary and nutritional complications of dysphagia. Attention to potential risks of anesthesia including impaired swallowing, increased risk of aspiration, reduced pulmonary function, and infection.</p><p><i>Surveillance:</i> In those with severe recurrent infections or undergoing immunomodulatory therapy: monitoring of pulmonary function and other signs of pulmonary disease and early signs of malignancy (e.g., weight loss, bruising, localized pain or swelling).</p></div><div><h4 class="inline">Genetic counseling.</h4><p>A-T is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, the sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual have a 25% chance of being affected, a 50% chance of being asymptomatic carriers, and a 25% chance of being unaffected and not carriers. <i>ATM</i> heterozygotes (carriers) are at increased risk of developing cancer. Once the <i>ATM</i> pathogenic variants have been identified in an affected family member, <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> for at-risk relatives, prenatal testing of pregnancies at increased risk, and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="ataxia-telangiectas.Diagnosis"><h2 id="_ataxia-telangiectas_Diagnosis_">Diagnosis</h2><div id="ataxia-telangiectas.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Ataxia-telangiectasia (A-T) <b>should be suspected</b> in children who have the following clinical, MRI, and preliminary laboratory findings.</p><p><b>Clinical findings.</b> Progressive cerebellar dysfunction between ages one and four years manifests as:</p><ul><li class="half_rhythm"><div class="half_rhythm">Gait and truncal ataxia;</div></li><li class="half_rhythm"><div class="half_rhythm">Head tilting;</div></li><li class="half_rhythm"><div class="half_rhythm">Slurred speech;</div></li><li class="half_rhythm"><div class="half_rhythm">Oculomotor apraxia and abnormal ocular saccades.</div><div class="half_rhythm">"If oculomotor apraxia cannot be clearly documented in a cooperative patient, the diagnosis of A-T should be viewed with suspicion" [E Boder, pediatric neurologist and A-T pioneer (1909-1995)].</div></li></ul><p>Note: The diagnosis of A-T is most difficult in very young children: they do not yet exhibit all the characteristic features of A-T and are typically unable to cooperate during neurologic examination.</p><p><b>MRI.</b> The classic cerebellar findings are atrophy of the frontal and posterior vermis and both hemispheres. Note: Although a small cerebellum is not always apparent on MRI in young children, diffusion-weighted MRI allowed quantitation of cerebellar corticomotor pathway pathology in children as young as age three years, suggesting that this imaging may be useful in early confirmation of the diagnosis of A-T when the necessary equipment and expertise are available [<a class="bk_pop" href="#ataxia-telangiectas.REF.tavani.2003.315">Tavani et al 2003</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.almaawali.2012.1121">Al-Maawali et al 2012</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.sahama.2014a.1289">Sahama et al 2014a</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.sahama.2014b.521">Sahama et al 2014b</a>].</p><p><b>Preliminary laboratory findings</b></p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Newborn screening (NBS)</b> for severe combined immunodeficiency identifies reduced T-cell receptor excision circle (TREC) levels. This method of NBS most likely identifies the estimated 50% of children with A-T who have lymphopenia; however, it may be less sensitive in older children with A-T (in whom T cell lymphopenias are less severe) [<a class="bk_pop" href="#ataxia-telangiectas.REF.mallott.2013.540">Mallott et al 2013</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Serum concentration of alpha-fetoprotein (AFP)</b> is elevated above10 ng/mL in about 95% of individuals with A-T.</div><div class="half_rhythm">Note: (1) Serum AFP concentration may remain above normal in unaffected children until age 24 months. (2) Persistent elevation of AFP does not necessarily indicate ongoing cerebellar damage or correlate with prognosis.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Chromosome analysis.</b> A 7;14 <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/translocation/">translocation</a> is identified in 5%-15% of cells in routine chromosome studies of peripheral blood of individuals with A-T. The break points are commonly at 14q11 (the T-cell receptor-alpha <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a>) and at 14q32 (the B- cell immunoglobulin heavy chain receptor [IGH] locus).</div></li></ul></div><div id="ataxia-telangiectas.Establishing_the_Dia"><h3>Establishing the Diagnosis</h3><p>The diagnosis of A-T <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> either by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> to document the presence of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> (<a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a>) <i>ATM</i> pathogenic variants or (when available) by immunoblotting to test for absent or reduced ATM protein.</p><p><b>Molecular genetic testing</b> approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>.</p><p><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>ATM</i> is performed first, followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</p><p>Targeted analysis for the following <i>ATM</i> pathogenic variants in specific populations can be performed first when appropriate:</p><ul><li class="half_rhythm"><div>Amish: c.1564_1565delAG</div></li><li class="half_rhythm"><div>North African Jewish: <a class="figpopup" href="/books/NBK26468/table/ataxia-telangiectas.T.selected_atm_patho/?report=objectonly" target="object" rid-figpopup="figataxiatelangiectasTselectedatmpatho" rid-ob="figobataxiatelangiectasTselectedatmpatho">c.103C&#x0003e;T</a> (p.Arg35Ter)</div></li><li class="half_rhythm"><div>Sardinian: <a class="figpopup" href="/books/NBK26468/table/ataxia-telangiectas.T.selected_atm_patho/?report=objectonly" target="object" rid-figpopup="figataxiatelangiectasTselectedatmpatho" rid-ob="figobataxiatelangiectasTselectedatmpatho">c.3894dupT</a></div></li></ul><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>ATM</i> and other genes of interest, such as <i>PP2A</i> (see <a href="#ataxia-telangiectas.Differential_Diagnos">Differential Diagnosis</a>), may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><div id="ataxia-telangiectas.T.molecular_genetic" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Ataxia-Telangiectasia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK26468/table/ataxia-telangiectas.T.molecular_genetic/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ataxia-telangiectas.T.molecular_genetic_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ataxia-telangiectas.T.molecular_genetic_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_ataxia-telangiectas.T.molecular_genetic_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_ataxia-telangiectas.T.molecular_genetic_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_ataxia-telangiectas.T.molecular_genetic_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>ATM</i></td><td headers="hd_h_ataxia-telangiectas.T.molecular_genetic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_ataxia-telangiectas.T.molecular_genetic_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~90%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_ataxia-telangiectas.T.molecular_genetic_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Deletion/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> analysis&#x000a0;<sup>5</sup></td><td headers="hd_h_ataxia-telangiectas.T.molecular_genetic_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1%-2%&#x000a0;<sup>6</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="ataxia-telangiectas.TF.1.1"><p class="no_margin">See <a href="/books/NBK26468/#ataxia-telangiectas.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="ataxia-telangiectas.TF.1.2"><p class="no_margin">See <a href="#ataxia-telangiectas.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="ataxia-telangiectas.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may also include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="ataxia-telangiectas.TF.1.4"><p class="no_margin">Some known pathogenic variants, such as the deep <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> Midlands, UK variant, c.5763-1050A&#x0003e;G (formerly known as 5762ins137), will not be detected by routine <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>ATM</i> exons [<a class="bk_pop" href="#ataxia-telangiectas.REF.mcconville.1996.320">McConville et al 1996</a>]; however, targeted sequencing of deep intronic pathogenic variants increases the variant detection rate.</p></div></dd><dt>5. </dt><dd><div id="ataxia-telangiectas.TF.1.5"><p class="no_margin">Testing that identifies <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications not detectable by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of the coding and flanking <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> regions of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and <a class="def" href="/books/n/gene/glossary/def-item/chromosomal-microarray/">chromosomal microarray</a> (CMA) that includes this gene/<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> segment.</p></div></dd><dt>6. </dt><dd><div id="ataxia-telangiectas.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#ataxia-telangiectas.REF.telatar.1998.36">Telatar et al [1998]</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.cavalieri.2008.10">Cavalieri et al [2008]</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.zhang.2009.2046">Zhang et al [2009]</a></p></div></dd></dl></div></div></div><p><b>Immunoblotting for ATM protein</b> in a lymphoblastoid cell line (LCL) is more than 95% sensitive and more than 98% specific for diagnosing A-T [<a class="bk_pop" href="#ataxia-telangiectas.REF.chun.2003.437">Chun et al 2003</a>]. This testing may be performed to help interpret sequence variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> or confirm a diagnosis when only one <i>ATM</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified.</p><p>Of individuals with A-T:</p><ul><li class="half_rhythm"><div>About 90% have no detectable ATM protein (i.e., &#x0003c;15% of control levels);</div></li><li class="half_rhythm"><div>About 10% have trace amounts to 15% of control levels of ATM protein;</div></li><li class="half_rhythm"><div>About 1% have a near-normal amount of ATM protein that lacks ATM serine/threonine kinase activity (so-called "kinase-dead" protein) [<a class="bk_pop" href="#ataxia-telangiectas.REF.stewart.2001.30133">Stewart et al 2001</a>].</div></li></ul><p>Note: The presence of more than 15% ATM protein suggests one of the following:</p><ul><li class="half_rhythm"><div>Another diagnosis</div></li><li class="half_rhythm"><div>An <i>ATM</i> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant</div></li><li class="half_rhythm"><div>A leaky <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> <i>ATM</i> variant</div></li><li class="half_rhythm"><div>An <i>ATM</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> resulting in "kinase-dead" protein</div></li><li class="half_rhythm"><div>Possibly, a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding an ancillary ATM-activating phosphatase like <i>PP2A</i>. However, to the authors' knowledge, PP2A deficiency results mainly from somatic pathogenic <i>PP2A</i> variants in tumor cells or PP2A inhibitors. To date, a person with PP2A deficiency has not been described.</div></li></ul><p>For more detailed information on the interpretation of the results of ATM protein testing and research testing for ATM, click <a href="/books/NBK26468/bin/ataxia-telangiectas-Table3.pdf">here</a> (pdf).</p></div></div><div id="ataxia-telangiectas.Clinical_Characteris"><h2 id="_ataxia-telangiectas_Clinical_Characteris_">Clinical Characteristics</h2><div id="ataxia-telangiectas.Clinical_Description"><h3>Clinical Description</h3><div id="ataxia-telangiectas.Classic_AtaxiaTelang"><h4>Classic Ataxia-Telangiectasia</h4><p>The primary features of classic A-T:</p><ul><li class="half_rhythm"><div>Progressive gait and truncal ataxia with onset between ages one and four years</div></li><li class="half_rhythm"><div>Progressively slurred speech</div></li><li class="half_rhythm"><div>Oculomotor apraxia (inability to follow an object across visual fields)</div></li><li class="half_rhythm"><div>Choreoathetosis (writhing movements)</div></li><li class="half_rhythm"><div>Oculocutaneous telangiectasia (usually evident by age 6 years)</div></li><li class="half_rhythm"><div>Frequent infections (with accompanying evidence of serum and cellular immunodeficiencies)</div></li><li class="half_rhythm"><div>Hypersensitivity to ionizing radiation with increased susceptibility to cancer (usually leukemia or lymphoma)</div></li></ul><p>Other features:</p><ul><li class="half_rhythm"><div>Premature aging with strands of gray hair</div></li><li class="half_rhythm"><div>Endocrine abnormalities including insulin-resistant diabetes mellitus and premature ovarian failure (i.e., normal menarche followed by irregular menses and loss of ovarian function before age 40 years) [Author, personal observation]</div></li></ul><p>Although the clinical manifestations of A-T in its late stages vary little from family to family, the age of onset and rate of progression can vary considerably even within a family with multiple <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. For clinical reviews, see <a class="bk_pop" href="#ataxia-telangiectas.REF.boder.1985">Boder [1985]</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.woods.1992.169">Woods &#x00026; Taylor [1992]</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.gatti.2001">Gatti [2001]</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.taylor.2005.1009">Taylor &#x00026; Byrd [2005]</a>, and <a class="bk_pop" href="#ataxia-telangiectas.REF.verhagen.2012.561">Verhagen et al [2012]</a>.</p><p><b>Neurologic.</b> The most obvious characteristic of classic A-T is progressive cerebellar ataxia. Shortly after learning to walk, children with A-T begin to stagger. Although the neurologic status of some children appears to improve from age two to four years, ataxia subsequently progresses. (The transient improvement is probably attributable to the rapid learning curve of young children.)</p><p>The ataxia begins as purely truncal but within several years involves peripheral coordination as well. Writing and drawing are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> by age five years.</p><p>By age ten years, most children become confined to a wheelchair.</p><p>Slurred speech and oculomotor apraxia are noted early. Both horizontal and vertical saccadic eye movements are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> [<a class="bk_pop" href="#ataxia-telangiectas.REF.farr.2002.891">Farr et al 2002</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.onodera.2006.361">Onodera 2006</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.yakusheva.2007.973">Yakusheva et al 2007</a>]. Drooling is common.</p><p>Choreoathetosis is found in almost all individuals with A-T. Myoclonic jerking and intention tremors are present in about 25%.</p><p>All teenagers with classic A-T need help with dressing, eating, washing, and toileting.</p><p>Muscle strength is normal at first but wanes with disuse, especially in the legs. Contractures in the fingers and toes are common in older individuals. Deep tendon reflexes are decreased or absent in older individuals; plantar reflexes are upgoing or absent</p><p>Intelligence is typically normal; however, learning difficulties are common. Slow motor and verbal responses make it difficult for individuals to complete "timed" IQ tests. Many American and British individuals with classic A-T have finished high school with good grades; some have finished college or university, often with the assistance of aides and attentive parents and sibs.</p><p>Dystonia and adult-onset spinal muscular atrophy have also been observed (see <a href="#ataxia-telangiectas.NonClassic_Forms_of">Non-Classic Forms of Ataxia-Telangiectasia</a>).</p><p><b>Immunodeficiency</b>, present in 60%-80% of individuals with classic A-T, is variable and does not correlate well with the frequency, severity, or spectrum of infections. The most consistent immunodeficiency reported in classic A-T is poor antibody response to pneumococcal polysaccharide vaccines [<a class="bk_pop" href="#ataxia-telangiectas.REF.sanal.1999.326">Sanal et al 1999</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.nowakwegrzyn.2004.505">Nowak-Wegrzyn et al 2004</a>]. Serum concentration of the immunoglobulins IgA, IgE, and IgG2 is often reduced. NK lymphocyte levels are occasionally elevated, most notably in individuals from Costa Rica [<a class="bk_pop" href="#ataxia-telangiectas.REF.regueiro.2000.177">Regueiro et al 2000</a>].</p><p>The immunodeficiency is not progressive, and some evidence suggests that T-cell lymphopenia may normalize after age 20 years [<a class="bk_pop" href="#ataxia-telangiectas.REF.boder.1985">Boder 1985</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.woods.1992.169">Woods &#x00026; Taylor 1992</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.regueiro.2000.177">Regueiro et al 2000</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.gatti.2001">Gatti 2001</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.pashankar.2006.156">Pashankar et al 2006</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.staples.2008.214">Staples et al 2008</a>].</p><p>Of note, immune status was more seriously impaired in 80 individuals with A-T and two <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> <i>ATM</i> alleles: both T- and B-cell lymphopenia and more frequent recurrent sinopulmonary infections were observed [<a class="bk_pop" href="#ataxia-telangiectas.REF.staples.2008.214">Staples et al 2008</a>]. Children with lymphopenia tend to have the most deleterious pathogenic variants, lowest (enzymatic) ATM kinase levels, most severe phenotypes, most frequent sinopulmonary infections, and poorest prognosis [<a class="bk_pop" href="#ataxia-telangiectas.REF.verhagen.2012.561">Verhagen et al 2012</a>].</p><p><b>Infection.</b> In contrast to the spectrum of infection observed in most immunodeficiency disorders, the spectrum of infection in classic A-T does not include opportunistic infections. The frequency and severity of infections correlate more with ATM kinase levels and general nutritional status than with immune status.</p><p>Some individuals with classic A-T develop chronic bronchiectasis.</p><p>While individuals with frequent infections may occasionally benefit from prophylactic antibiotics and/or intravenous immunoglobulin (IVIG) replacement therapy [<a class="bk_pop" href="#ataxia-telangiectas.REF.nowakwegrzyn.2004.505">Nowak-Wegrzyn et al 2004</a>], longevity has increased substantially even in those not receiving IVIG.</p><p><b>Pulmonary.</b> In older individuals, pulmonary failure, with or without identifiable infections, is a major cause of failing health and death [<a class="bk_pop" href="#ataxia-telangiectas.REF.lockman.2012.256">Lockman et al 2012</a>]. Life-threatening lymphocytic infiltration of the lung has been reported [<a class="bk_pop" href="#ataxia-telangiectas.REF.tangsinmankong.2001.939">Tangsinmankong et al 2001</a>].</p><p><b>Other findings.</b> Liver enzyme levels are often elevated in A-T, without apparent liver pathology. (Thus, liver biopsy is usually not revealing.)</p><p><b>Cancer.</b> The risk for malignancy in individuals with classic A-T is 38%.</p><p>Leukemia and lymphoma account for about 85% of malignancies. Younger children tend to have acute lymphocytic leukemia (ALL) of T-cell origin and older children are likely to have an aggressive T-cell leukemia. Lymphomas are usually B-cell types.</p><p>As individuals with classic A-T are living longer, other cancers and tumors including ovarian cancer, breast cancer, gastric cancer, melanoma, leiomyomas, and sarcomas have also been observed.</p><p><b>Life expectancy.</b> Over the past 25 years, for reasons that are unclear, the life expectancy of individuals with A-T has increased considerably. Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals now live beyond age 25 years. Some have survived into their 50s [<a class="bk_pop" href="#ataxia-telangiectas.REF.d_rk.2004.272">D&#x000f6;rk et al 2004</a>; <a class="bk_pop" href="#ataxia-telangiectas.REF.crawford.2006.610">Crawford et al 2006</a>; Author, unpublished observations].</p><p><b>Pathology.</b> The cerebellum atrophies early in the course of classic A-T, being visibly smaller on MRI by age seven or eight years, with concomitant loss of Purkinje cells and depletion of granule cells [<a class="bk_pop" href="#ataxia-telangiectas.REF.sardanelli.1995.77">Sardanelli et al 1995</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.tavani.2003.315">Tavani et al 2003</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.wallis.2007.79">Wallis et al 2007</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.lin.2014.119">Lin et al 2014</a>].</p><p>At autopsy, virtually all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have a small embryonic-like thymus, lacking Hassall's corpuscles.</p><p>Microscopic nucleomegaly (i.e., irregular size and shape of nuclei) is a classic histologic characteristic of A-T cells and is used by pathologists in interpreting tissue changes in organs from persons with A-T. Nucleomegaly is easily appreciated in tissues where the architecture is otherwise very uniform, such as renal tubules and seminal ducts. Nucleomegaly most likely reflects perturbed cell cycle checkpoints and poor fidelity of DNA repair mechanisms and DNA processing.</p></div><div id="ataxia-telangiectas.NonClassic_Forms_of"><h4>Non-Classic Forms of Ataxia-Telangiectasia</h4><p>Other phenotypes associated with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> (<a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a>) <i>ATM</i> pathogenic variants include the following:</p><ul><li class="half_rhythm"><div>Milder A-T phenotypes including adult-onset A-T [<a class="bk_pop" href="#ataxia-telangiectas.REF.mcconville.1996.320">McConville et al 1996</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.stankovic.1998.334">Stankovic et al 1998</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.saviozzi.2002.57">Saviozzi et al 2002</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.mitui.2009.12">Mitui et al 2009</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.verhagen.2012.561">Verhagen et al 2012</a>]</div></li><li class="half_rhythm"><div>A-T<sub>Fresno</sub>, a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> that combines features of <a href="/books/n/gene/nijmegen/">Nijmegen breakage syndrome</a> (NBS) and classic A-T [<a class="bk_pop" href="#ataxia-telangiectas.REF.curry.1989.270">Curry et al 1989</a>]. Biallelic <i>ATM</i> pathogenic variants have been identified in most such <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals in whom <i>ATM</i> has been sequenced [<a class="bk_pop" href="#ataxia-telangiectas.REF.gilad.1998.551">Gilad et al 1998</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.chun.2004.1187">Chun &#x00026; Gatti 2004</a>].</div></li><li class="half_rhythm"><div>Early-onset dystonia or hypotonia in extended Mennonite families, with high cancer frequency and adverse responses to chemotherapeutic agents associated with a common <i>ATM</i> haplotype and homozygosity for the <i>ATM</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, <a class="figpopup" href="/books/NBK26468/table/ataxia-telangiectas.T.selected_atm_patho/?report=objectonly" target="object" rid-figpopup="figataxiatelangiectasTselectedatmpatho" rid-ob="figobataxiatelangiectasTselectedatmpatho">c.6200C&#x0003e;A</a> [<a class="bk_pop" href="#ataxia-telangiectas.REF.yanofsky.2009.462">Yanofsky et al 2009</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.saunderspullman.2012.649">Saunders-Pullman et al 2012</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.nakamura.2014.332">Nakamura et al 2014</a>]</div></li><li class="half_rhythm"><div>Progressive dystonia, the presenting manifestation in some individuals who were later diagnosed with A-T [<a class="bk_pop" href="#ataxia-telangiectas.REF.bodensteiner.1980.464">Bodensteiner et al 1980</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.woods.1992.169">Woods &#x00026; Taylor 1992</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.goyal.2002.187">Goyal &#x00026; Behari 2002</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.verhagen.2009.430">Verhagen et al 2009</a>]</div></li><li class="half_rhythm"><div>Three sibs with levodopa-responsive cervical dystonia and conjunctival telangiectasia who were compound heterozygotes for the <a class="figpopup" href="/books/NBK26468/table/ataxia-telangiectas.T.selected_atm_patho/?report=objectonly" target="object" rid-figpopup="figataxiatelangiectasTselectedatmpatho" rid-ob="figobataxiatelangiectasTselectedatmpatho">c.7886_7890delTATTA</a> <a class="def" href="/books/n/gene/glossary/def-item/frameshift-variant/">frameshift variant</a> and the <a class="figpopup" href="/books/NBK26468/table/ataxia-telangiectas.T.selected_atm_patho/?report=objectonly" target="object" rid-figpopup="figataxiatelangiectasTselectedatmpatho" rid-ob="figobataxiatelangiectasTselectedatmpatho">c.6154G&#x0003e;A</a> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>/<a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variant; two first-cousin sibs with A-T without dystonia were <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the c.7886_7890delTATTA frameshift variant [<a class="bk_pop" href="#ataxia-telangiectas.REF.charlesworth.2013.1148">Charlesworth et al 2013</a>]. All five <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals had elevated levels of alpha-fetoprotein.</div></li><li class="half_rhythm"><div>Adult-onset spinal muscular atrophy [<a class="bk_pop" href="#ataxia-telangiectas.REF.hiel.2006.346">Hiel et al 2006</a>], also associated with reduced levels of ATM protein</div></li><li class="half_rhythm"><div>Breast cancer followed by late-onset A-T in two families with compound heterozygosity for <a class="figpopup" href="/books/NBK26468/table/ataxia-telangiectas.T.selected_atm_patho/?report=objectonly" target="object" rid-figpopup="figataxiatelangiectasTselectedatmpatho" rid-ob="figobataxiatelangiectasTselectedatmpatho">c.1A&#x0003e;G</a> and a different second <i>ATM</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#ataxia-telangiectas.REF.byrd.2012.262">Byrd et al 2012</a>; Blancato et al, unpublished]. See <a href="#ataxia-telangiectas.GenotypePhenotype_Co">Genotype-Phenotype Correlations</a>.</div></li></ul></div><div id="ataxia-telangiectas.Heterozygotes"><h4>Heterozygotes</h4><p>The cancer risk of individuals <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>ATM</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is approximately four times that of the general population, primarily because of the increased risk for breast cancer [<a class="bk_pop" href="#ataxia-telangiectas.REF.swift.1991.1831">Swift et al 1991</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.stankovic.1998.334">Stankovic et al 1998</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.bretsky.2003.733">Bretsky et al 2003</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.bernstein.2006.1122">Bernstein et al 2006</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.renwick.2006.873">Renwick et al 2006</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.concannon.2008.6486">Concannon et al 2008</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.tavtigian.2009.427">Tavtigian et al 2009</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.van_os.2016.105">van Os et al 2016</a>].</p><p>Cancer risk probably depends on multiple factors including tumor type, age at cancer onset, and whether the individual is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> or a truncating variant [<a class="bk_pop" href="#ataxia-telangiectas.REF.gatti.2001">Gatti 2001</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.concannon.2002.89">Concannon 2002</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.scott.2002.925">Scott et al 2002</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.spring.2002.185">Spring et al 2002</a>].</p><p><i>ATM</i> variants associated with breast cancer tend to be <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> changes whereas <i>ATM</i> missense variants in individuals with A-T only are uncommon (&#x0003c;10%) [<a class="bk_pop" href="#ataxia-telangiectas.REF.gatti.1999.419">Gatti et al 1999</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.bernstein.2003.1513">Bernstein et al 2003</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.tavtigian.2009.427">Tavtigian et al 2009</a>]. Meta-analyses estimate a relative risk of three- to fourfold that in comparable general populations.</p><p><i>ATM</i> pathogenic variants have been reported in both tumor cells and <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> cells in several types of leukemia and lymphoma, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), T-cell prolymphocytic leukemia (T-PLL), and mantle zone lymphoma [<a class="bk_pop" href="#ataxia-telangiectas.REF.stankovic.1998.334">Stankovic et al 1998</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.stilgenbauer.2000.127">Stilgenbauer et al 2000</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.oguchi.2003.3622">Oguchi et al 2003</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.eclache.2004.72">Eclache et al 2004</a>].</p><p>T-cell ALL-associated <i>ATM</i> pathogenic variants are similar to those seen in individuals with A-T [<a class="bk_pop" href="#ataxia-telangiectas.REF.liberzon.2004.161">Liberzon et al 2004</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.pylk_s.2007.1040">Pylk&#x000e4;s et al 2007</a>].</p></div></div><div id="ataxia-telangiectas.GenotypePhenotype_Co"><h3>Genotype-Phenotype Correlations</h3><p>The <a class="figpopup" href="/books/NBK26468/table/ataxia-telangiectas.T.selected_atm_patho/?report=objectonly" target="object" rid-figpopup="figataxiatelangiectasTselectedatmpatho" rid-ob="figobataxiatelangiectasTselectedatmpatho">c.5762-1050A&#x0003e;G</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (formerly referred to as 5762ins137 [<a class="bk_pop" href="#ataxia-telangiectas.REF.sutton.2004.891">Sutton et al 2004</a>]) is associated with a somewhat slower rate of neurologic deterioration, later onset of manifestations, intermediate radiosensitivity, and little or no cancer risk [<a class="bk_pop" href="#ataxia-telangiectas.REF.mcconville.1996.320">McConville et al 1996</a>].</p><p>The pathogenic variants <a class="figpopup" href="/books/NBK26468/table/ataxia-telangiectas.T.selected_atm_patho/?report=objectonly" target="object" rid-figpopup="figataxiatelangiectasTselectedatmpatho" rid-ob="figobataxiatelangiectasTselectedatmpatho">c.1A&#x0003e;G</a>, <a class="figpopup" href="/books/NBK26468/table/ataxia-telangiectas.T.selected_atm_patho/?report=objectonly" target="object" rid-figpopup="figataxiatelangiectasTselectedatmpatho" rid-ob="figobataxiatelangiectasTselectedatmpatho">c.7271T&#x0003e;G</a>, <a class="figpopup" href="/books/NBK26468/table/ataxia-telangiectas.T.selected_atm_patho/?report=objectonly" target="object" rid-figpopup="figataxiatelangiectasTselectedatmpatho" rid-ob="figobataxiatelangiectasTselectedatmpatho">c.8147T&#x0003e;C</a>, and <a class="figpopup" href="/books/NBK26468/table/ataxia-telangiectas.T.selected_atm_patho/?report=objectonly" target="object" rid-figpopup="figataxiatelangiectasTselectedatmpatho" rid-ob="figobataxiatelangiectasTselectedatmpatho">c.8494C&#x0003e;T</a> have been associated with the following:</p><ul><li class="half_rhythm"><div class="half_rhythm">A milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and longer life span [<a class="bk_pop" href="#ataxia-telangiectas.REF.stankovic.1998.334">Stankovic et al 1998</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.verhagen.2009.430">Verhagen et al 2009</a>]. However, the limited number of individuals with these pathogenic variants and the lack of individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for these variants preclude making statistically significant correlations.</div></li><li class="half_rhythm"><div class="half_rhythm">An increased cancer risk, as is the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> c.6679C&#x0003e;T [<a class="bk_pop" href="#ataxia-telangiectas.REF.bernstein.2006.1122">Bernstein et al 2006</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.mitui.2009.12">Mitui et al 2009</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.tavtigian.2009.427">Tavtigian et al 2009</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.byrd.2012.262">Byrd et al 2012</a>]</div><div class="half_rhythm">Of note, c.1A&#x0003e;G was found in two unrelated families (with three <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals who presented with breast cancer after age 40 years), with no ataxia or other neurologic findings until after chemotherapy and adverse reactions to radiation therapy. Radiosensitivity and <i>ATM</i> pathogenic variants were identified in all three [<a class="bk_pop" href="#ataxia-telangiectas.REF.byrd.2012.262">Byrd et al 2012</a>; Blancato et al, unpublished].</div></li></ul></div><div id="ataxia-telangiectas.Nomenclature"><h3>Nomenclature</h3><p>Ataxia-telangiectasia was previously referred to as Louis-Bar syndrome.</p></div><div id="ataxia-telangiectas.Prevalence"><h3>Prevalence</h3><p>The prevalence of A-T in the US is 1:40,000-1:100,000 live births. Prevalence varies with the degree of <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a> in a country.</p><p>A-T is the most common cause of progressive cerebellar ataxia in childhood in most countries with low coefficients of inbreeding; <a href="/books/n/gene/aoa/">Ataxia with oculomotor apraxia type 1</a> and <a href="/books/n/gene/aoa2/">Ataxia with oculomotor apraxia type 2</a> may be more prevalent in Portugal and perhaps Japan [<a class="bk_pop" href="#ataxia-telangiectas.REF.n_meth.2000.1320">N&#x000e9;meth et al 2000</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.date.2001.184">Date et al 2001</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.moreira.2001.189">Moreira et al 2001</a>].</p></div></div><div id="ataxia-telangiectas.GeneticallyRelated_A"><h2 id="_ataxia-telangiectas_GeneticallyRelated_A_">Genetically-Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>ATM</i>.</p></div><div id="ataxia-telangiectas.Differential_Diagnos"><h2 id="_ataxia-telangiectas_Differential_Diagnos_">Differential Diagnosis</h2><p>The diagnosis of ataxia telangiectasia (A-T) is questionable when accompanied by severe intellectual disability, seizures, non-progressive ataxia, or microcephaly. Early seizures and microcephaly (especially in an infant of Middle Eastern origin) suggest the diagnosis of microcephaly, seizures, and developmental delay (MCSZ) caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>PNKP</i> (encoding polynucleotide kinase phosphatase) [<a class="bk_pop" href="#ataxia-telangiectas.REF.shen.2010.245">Shen et al 2010</a>] (OMIM <a href="http://omim.org/entry/605610" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">605610</a>). Cells from these patients have DNA repair deficiencies and are sensitive to ionizing radiation [<a class="bk_pop" href="#ataxia-telangiectas.REF.shen.2010.245">Shen et al 2010</a>; Gatti RA, unpublished data].</p><p>Of note, elevated serum AFP has been described in only four inherited ataxias: A-T; a non-classic form of A-T described as dopa-responsive dystonia observed in three sibs with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>ATM</i> pathogenic variants [<a class="bk_pop" href="#ataxia-telangiectas.REF.charlesworth.2013.1148">Charlesworth et al 2013</a>]; <a href="/books/n/gene/aoa2/">ataxia with oculomotor apraxia type 2</a> (AOA2); and RNF168 deficiency.</p><p><i>ATM</i> is a ubiquitous house-keeping <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, present in every nucleated cell. As a serine-threonine kinase, the ATM protein phosphorylates or activates many proteins/substrates and interacts with many different molecules and protein complexes; thus, clinical phenocopies of A-T are common.</p><p>The proteins nibrin, Mre11, and RAD50 interact with ATM to localize the DNA damage and choreograph/coordinate the almost instantaneous repair of double-strand DNA breaks before the next cell replication [<a class="bk_pop" href="#ataxia-telangiectas.REF.lavin.2015.2877">Lavin et al 2015</a>]. Without such urgent repair, this commonly occurring DNA damage becomes lethal during the next cell division, leading to more complex lesions such as chromosomal aberrations, cancers, or cell death.</p><p>To date, an increased mode of t(7;14) translocations has been observed exclusively in individuals with one of the four disorders: A-T, Nijmegen breakage syndrome, Mre11 deficiency, or RAD50 deficiency; the mechanism is not understood.</p><p>It is also clear that DNA double strand breaks are even more devastating to non-dividing neural cells, suggesting that these early steps of DNA repair are still incompletely understood.</p><ul><li class="half_rhythm"><div><a href="/books/n/gene/nijmegen/"><b>Nijmegen breakage syndrome</b></a>
<b>(NBS).</b> Biallelic pathogenic variants in <i>NBN</i> (encoding nibrin) are causative. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</div><ul><li class="half_rhythm"><div><b>Clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</b> Individuals with NBS are immunodeficient and most are intellectually impaired and microcephalic; more than one third develop cancer. Individuals with NBS do not develop ataxia or telangiectasia. Their symptoms overlap with A-T<sub>Fresno</sub> (see <a href="#ataxia-telangiectas.NonClassic_Forms_of">Non-Classic Forms of Ataxia-Telangiectasia</a>). NBS also includes the phenotype Berlin breakage syndrome</div></li><li class="half_rhythm"><div><b>Other.</b> NBS cells are very sensitive to ionizing radiation.</div></li></ul></li><li class="half_rhythm"><div><b>Mre11-deficient ataxia</b> (OMIM <a href="http://omim.org/entry/604391" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">604391</a>). Biallelic pathogenic variants in <i>MRE11</i> are causative. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</div><ul><li class="half_rhythm"><div><b>Clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</b> Ataxia</div></li><li class="half_rhythm"><div><b>Other.</b> Serum AFP concentration is normal. Cells show increased radiosensitivity [<a class="bk_pop" href="#ataxia-telangiectas.REF.stewart.1999.577">Stewart et al 1999</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.pitts.2001.1155">Pitts et al 2001</a>].</div></li></ul></li><li class="half_rhythm"><div><b>RAD50 deficiency</b> (OMIM <a href="http://omim.org/entry/604040" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">604040</a>) has been observed in two unrelated individuals of German descent, a female age 28 years [<a class="bk_pop" href="#ataxia-telangiectas.REF.waltes.2009.605">Waltes et al 2009</a>] and a male age 18 years [<a class="bk_pop" href="#ataxia-telangiectas.REF.brown.2016">Brown et al 2016</a>]. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>. Both had different <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>RAD50</i> and both were also <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>NBN</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div><ul><li class="half_rhythm"><div><b>Clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</b> The female had microcephaly, developmental delay, mild spasticity, a slight non-progressive ataxia, and short stature. She had no history of cancer. The male had normal stature and a history of chronic respiratory illness. At age 16 years, he developed T cell acute lymphocytic leukemia (ALL) (Ph+).</div></li><li class="half_rhythm"><div><b>Other.</b> Cells with translocations of chromosomes 7 and 14 were observed in both. The cells from the male scored as radiosensitive in a colony survival assay [<a class="bk_pop" href="#ataxia-telangiectas.REF.sun.2002.724">Sun et al 2002</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.brown.2016">Brown et al 2016</a>].</div></li></ul></li><li class="half_rhythm"><div><b>RNF168 deficiency</b> (OMIM <a href="http://omim.org/entry/612688" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">612688</a>) or RIDDLE (<i>r</i>adiosensitivity, <i>i</i>mmuno<i>d</i>eficiency, <i>d</i>ysmorphic features, and <i>le</i>arning difficulties) syndrome (OMIM <a href="http://omim.org/entry/611943" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">611943</a>) is caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>RNF168</i>. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</div><ul><li class="half_rhythm"><div><b>Clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</b> Ataxia and telangiectasia [<a class="bk_pop" href="#ataxia-telangiectas.REF.stewart.2009.420">Stewart et al 2009</a>]. <a class="bk_pop" href="#ataxia-telangiectas.REF.devgan.2011.1500">Devgan et al [2011]</a> described a man with ataxia (without apraxia or dysarthria), growth retardation, microcephaly, immunodeficiency, and an elevated serum AFP who died of respiratory failure at age 30 years.</div></li><li class="half_rhythm"><div><b>Other.</b> RNF168 protein is absent and ATM protein levels are normal.</div></li></ul></li></ul><p>Furthermore, virtually without exception, cells in these AT-like phenocopies are hypersensitive to x-rays and DNA damaging agents which are commonly used in cancer treatment. It is now even possible to encounter individuals with XCIND (<i>x-</i>ray <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a>, <i>c</i>ancer, <i>i</i>mmunodeficiency, <i>n</i>europathology, and <i>D</i>NA repair deficiency) whose disorder has not yet been causally linked to a specific DNA repair <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or pathway [<a class="bk_pop" href="#ataxia-telangiectas.REF.gatti.2007.87">Gatti et al 2007</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.du.2009.116">Du &#x00026; Gatti 2009</a>]. Cells from individuals with XCIND scored as "radiosensitive" in a colony survival assay [<a class="bk_pop" href="#ataxia-telangiectas.REF.sun.2002.724">Sun et al 2002</a>]. Such individuals would be predicted to be cancer prone.</p><p>Other disorders with childhood-onset ataxia (see <a href="/books/n/gene/ataxias/">Ataxia Overview</a> for discussion):</p><ul><li class="half_rhythm"><div><a href="/books/n/gene/aoa/">Ataxia with oculomotor apraxia type 1</a> (AOA1 or aprataxin deficiency)</div></li><li class="half_rhythm"><div><a href="/books/n/gene/aoa2/">Ataxia with oculomotor apraxia type 2</a> (AOA2 or senataxin deficiency). Like A-T, AOA2 is associated with an elevated serum concentration of alpha-fetoprotein.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/ataxias/">Autosomal recessive spinocerebellar ataxia 9</a> (SCAR9), associated with CoQ<sub>10</sub> deficiency [<a class="bk_pop" href="#ataxia-telangiectas.REF.lagiertourenne.2008.661">Lagier-Tourenne et al 2008</a>]</div></li><li class="half_rhythm"><div><a href="/books/n/gene/sca-io/">Infantile-onset spinocerebellar ataxia</a> (IOSCA) caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>TWNK</i> (previously <i>C10orf2</i>)</div></li><li class="half_rhythm"><div>Sensory ataxic neuropathy with dysarthria and ophthalmoplegia (SANDO), caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>POLG.</i> (See <a href="/books/n/gene/alpers/"><i>POLG</i>-Related Disorders</a>.)</div></li><li class="half_rhythm"><div><a href="/books/n/gene/sider-anemia/">X-linked sideroblastic anemia and ataxia</a>, caused by mutation of <i>ABCB7</i></div></li></ul></div><div id="ataxia-telangiectas.Management"><h2 id="_ataxia-telangiectas_Management_">Management</h2><div id="ataxia-telangiectas.Evaluations_Followin"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with ataxia-telangiectasia (A-T), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Neurologic consultation with attention to ataxia, including assessment of extraocular movement</div></li><li class="half_rhythm"><div>Assessment of speech re communication and swallowing re risk of aspiration</div></li><li class="half_rhythm"><div>Nutrition and feeding assessment</div></li><li class="half_rhythm"><div>Immune status of specific parameters that were previously aberrant (e.g., immunoglobulin levels, B/T cell levels, T cell function)</div></li><li class="half_rhythm"><div>Chest x-ray and pulmonary function for baseline</div></li><li class="half_rhythm"><div>CBC with differential</div></li><li class="half_rhythm"><div>Diabetes screen (urinalysis, fasting blood glucose concentration, Hgb A1C)</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="ataxia-telangiectas.Treatment_of_Manifes"><h3>Treatment of Manifestations</h3><p><b>Neurologic</b>. Supportive therapy can minimize drooling, choreoathetosis, myoclonus/tremor, and ataxia. However, individual responses to specific medications (e.g., amantadine and 4-aminopyridine) and to treatments used for myoclonus vary [<a class="bk_pop" href="#ataxia-telangiectas.REF.perlman.2012.307">Perlman et al 2012</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.nissenkorn.2013.155">Nissenkorn et al 2013</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.shaikh.2013.2728">Shaikh et al 2013</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.van_egmond.2015.726">van Egmond et al 2015</a>]. Thus, it is recommended that treatment options be discussed with an experienced neurologist.</p><p>Early and continued physical therapy can minimize the risk for contractures (which appear in almost all individuals with time and often lead to other problems such as pressure sores and pain) and scoliosis (which can, for example, be the consequence of prolonged sitting in a wheelchair &#x02013; particularly the tendency to lean on the same elbow).</p><p>Although steroids are reported to temporarily improve the neurologic symptoms of A-T in children, the symptoms reappear within days of their discontinuation [<a class="bk_pop" href="#ataxia-telangiectas.REF.gatti.1985">Gatti 1985</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.buoni.2006.1479">Buoni et al 2006</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.broccoletti.2008.223">Broccoletti et al 2008</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.gatti.2009.653">Gatti &#x00026; Perlman 2009</a>]. (See also <a href="#ataxia-telangiectas.Therapies_Under_Inve">Therapies Under Investigation</a>.)</p><p><b>Immunodeficiency.</b> IVIG replacement therapy should be considered for individuals with frequent and severe infections and very low IgG levels [<a class="bk_pop" href="#ataxia-telangiectas.REF.nowakwegrzyn.2004.505">Nowak-Wegrzyn et al 2004</a>].</p><p><b>Pulmonary.</b> The European Respiratory Society (ERS) has prepared extensive guidelines for the multidisciplinary respiratory management of A-T, emphasizing the need for monitoring of immune function, recurrent infection, pulmonary function, swallowing, nutrition, and scoliosis, all of which can contribute to increased respiratory morbidity and mortality in persons with A-T [<a class="bk_pop" href="#ataxia-telangiectas.REF.bhatt.2015.565">Bhatt et al 2015</a>] (<a href="http://err.ersjournals.com/content/24/138/565" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>).</p><p><b>Cancer.</b> Because cells from individuals with A-T are 30% more sensitive to ionizing radiation than cells from controls, conventional doses of ionizing radiation are potentially lethal in individuals with A-T. Thus, the use of radiotherapy and some radiomimetic chemotherapeutic agents should be administered carefully and monitored closely [<a class="bk_pop" href="#ataxia-telangiectas.REF.sch_tte.2016.143">Sch&#x000fc;tte et al 2016</a>].</p><p>Doses of some chemotherapeutic agents are often reduced by 25%-50% and longer recovery periods between treatments are considered to allow for the slower DNA repair that occurs in A-T [<a class="bk_pop" href="#ataxia-telangiectas.REF.sch_tte.2016.143">Sch&#x000fc;tte et al 2016</a>].</p></div><div id="ataxia-telangiectas.Prevention_of_Second"><h3>Prevention of Secondary Complications</h3><p>Pulmonary and nutritional complications of dysphagia are common. Often, gastrostomy tube feedings are recommended to manage these comorbidities. Children with disorders with predictable progression (like A-T) and impaired swallowing may benefit from early rather than late placement of a feeding tube [<a class="bk_pop" href="#ataxia-telangiectas.REF.leftongreif.2000.225">Lefton-Greif et al 2000</a>].</p><p>Anesthesia carries unique potential risks in persons with A-T because of impaired coordination of swallowing, increased risk of aspiration, reduced respiratory capacity, and propensity to infections [<a class="bk_pop" href="#ataxia-telangiectas.REF.mcgrathmorrow.2008.59">McGrath-Morrow et al 2008</a>]. In a recent review, 24% of patients required supplemental oxygen (maximum duration 24 hours) post anesthesia; mild postoperative hypothermia was also relatively common [<a class="bk_pop" href="#ataxia-telangiectas.REF.lockman.2012.256">Lockman et al 2012</a>].</p></div><div id="ataxia-telangiectas.Surveillance"><h3>Surveillance</h3><p>The European Respiratory Society (ERS) has prepared extensive guidelines for the multidisciplinary respiratory management of A-T, emphasizing the need for monitoring of immune function, recurrent infection, pulmonary function, swallowing, nutrition, and scoliosis, all of which could contribute to increased respiratory morbidity and mortality in A-T [<a class="bk_pop" href="#ataxia-telangiectas.REF.bhatt.2015.565">Bhatt et al 2015</a>] (<a href="http://err.ersjournals.com/content/24/138/565" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>).</p><p>Parents should be counseled to monitor for &#x02013; and report to a physician &#x02013; the early warning signs of malignancy (which can occur at any age) including weight loss, bruising, and localized pain or swelling. Periodic CBCs are warranted.</p><p>Immune status needs to be monitored if severe recurrent infections occur or immunomodulatory therapy is in progress.</p></div><div id="ataxia-telangiectas.Evaluation_of_Relati"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#ataxia-telangiectas.Related_Genetic_Coun">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="ataxia-telangiectas.Therapies_Under_Inve"><h3>Therapies Under Investigation</h3><p>Research suggests the following:</p><ul><li class="half_rhythm"><div class="half_rhythm">Antioxidants (e.g., vitamin E or alpha-lipoic acid) are recommended, although no formal testing for efficacy has been conducted in individuals with A-T. Alpha-lipoic acid has the theoretic advantage of crossing the blood-brain barrier and improving mitochondrial function in A-T cells [<a class="bk_pop" href="#ataxia-telangiectas.REF.ambrose.2007.2154">Ambrose et al 2007</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">In culture, certain aminoglycoside antibiotics can induce small amounts of full-length ATM protein and return ATM functions to A-T cells with primary <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> pathogenic variants [<a class="bk_pop" href="#ataxia-telangiectas.REF.lai.2004.15676">Lai et al 2004</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.gatti.2012.33">Gatti 2012</a>]. Non-aminoglycoside read-through chemicals, identified by a high-throughput screen of 70,000 compounds, induce ATM protein in A-T cells [<a class="bk_pop" href="#ataxia-telangiectas.REF.du.2009.116">Du &#x00026; Gatti 2009</a>]; and chemical derivatives of those compounds &#x02013; such as RTC13, RTC14, RTC216, RTC202, RTC204, and RTC219 &#x02013; have produced encouraging results in other diseases besides A-T (e.g., a mouse model of Duchenne muscular dystrophy [<a class="bk_pop" href="#ataxia-telangiectas.REF.kayali.2012.4007">Kayali et al 2012</a>], epidermolysis bullosa keratinocytes, xeroderma pigmentosum [<a class="bk_pop" href="#ataxia-telangiectas.REF.kuschal.2013.19483">Kuschal et al 2013</a>], and retinal cells from amaurotic <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> blindness [<a class="bk_pop" href="#ataxia-telangiectas.REF.pillers.2015">Pillers et al 2015</a>].</div><div class="half_rhythm">Thus, it is anticipated that in future patients will be candidates for mutation-targeted therapeutic trials, which will be based on the class of pathogenic variants present and not on the specific <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> itself. These drugs will be grouped according to the class of pathogenic variants for which they can address/correct the underlying molecular pathogenicity. &#x02013; rendering them potentially useful for treating a molecular spectrum of genetic diseases based on the class of <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> rather than the disease itself [<a class="bk_pop" href="#ataxia-telangiectas.REF.du.2007.6007">Du et al 2007</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.hu.2008.540">Hu &#x00026; Gatti 2008</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.du.2009.116">Du &#x00026; Gatti 2009</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.jung.2011.5842">Jung et al 2011</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.gatti.2012.33">Gatti 2012</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.du.2013.1653">Du et al 2013</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.lavin.2013.1650">Lavin 2013</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Antisense morpholino oligonucleotides (AMOs) induce substantial corrections of ATM protein in cell lines with certain types of <i>ATM</i> <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variants [<a class="bk_pop" href="#ataxia-telangiectas.REF.du.2007.6007">Du et al 2007</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.du.2009.2285">Du et al 2009</a>]. AMOs remain active in A-T cells for more than 14 days. In animal studies, they are well tolerated when a cell-penetrating protein moiety is added to the AMO. Groundbreaking clinical trials using AMO to treat spinal muscular atrophy &#x02013; and a particular splicing variant that causes Duchenne muscular dystrophy &#x02013; are in progress.</div></li><li class="half_rhythm"><div class="half_rhythm">Amlexanox (Aphthasol<sup>&#x000ae;</sup>) is another non-aminoglycoside (similar to ataluren [PTC124]) read-through compound for <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> pathogenic variants that is being tested. To date, it is approved as an ointment for mouth ulcers and is prescribed primarily by dentists [<a class="bk_pop" href="#ataxia-telangiectas.REF.loudon.2013.79">Loudon 2013</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Dexamethasone and betamethasone, but not methylprednisolone, have been reported to decrease neurologic manifestations in A-T [<a class="bk_pop" href="#ataxia-telangiectas.REF.buoni.2006.1479">Buoni et al 2006</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.broccoletti.2008.223">Broccoletti et al 2008</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.gatti.2009.653">Gatti &#x00026; Perlman 2009</a>]. However, the neurologic improvement, which is also accompanied by signs of steroid toxicity, disappears within days of discontinuation of the steroids. Additional studies are in progress. Delivery of the steroids by loading them into erythrocytes affords much better dose control and delivery at 0.001% of previous steroid doses [<a class="bk_pop" href="#ataxia-telangiectas.REF.leuzzi.2015.e98">Leuzzi et al 2015</a>].</div><div class="half_rhythm">In a formal clinical trial in progress, betamethasone is being delivered within autologous red cells that have been infused with doses 100-1000 times lower than what was previously manageable, thereby mitigating most side effects of chronic steroid therapy.</div></li><li class="half_rhythm"><div class="half_rhythm">Use of insulin-like growth factor 1(IGF-1) treatment for A-T has been suggested [<a class="bk_pop" href="#ataxia-telangiectas.REF.fernandez.2005.134">Fernandez et al 2005</a>]. More recently, <a class="bk_pop" href="#ataxia-telangiectas.REF.voss.2014.123">Voss et al [2014]</a> showed that the GH/IGF-1 axis was perturbed in 58.3% of individuals with A-T (age range 2 to 9 years). A clinical trial is presently underway.</div></li><li class="half_rhythm"><div class="half_rhythm">Manganese-containing superoxide dismutase (SOD) mimics have a radioprotective effect on A-T cells [<a class="bk_pop" href="#ataxia-telangiectas.REF.pollard.2009.250">Pollard et al 2009</a>]. A recent report provides compelling evidence that treatment of a transgenic mouse model of amyotrophic lateral sclerosis (ALS) with a copper-chaperone for SOD extends by 500 days the life expectancy of mice that normally die within three months [<a class="bk_pop" href="#ataxia-telangiectas.REF.williams.2016.1">Williams et al 2016</a>]. This potential advance in treating motor degeneration may be applicable to A-T as well.</div></li><li class="half_rhythm"><div class="half_rhythm">Mutation-targeted therapy for other rare genetic diseases has been encouraging [<a class="bk_pop" href="#ataxia-telangiectas.REF.wilschanski.2003.1433">Wilschanski et al 2003</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.welch.2007.87">Welch et al 2007</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.du.2009.2285">Du et al 2009</a>]. The number of potential disease targets for read-through therapy exceeds 8000 [<a class="bk_pop" href="#ataxia-telangiectas.REF.keeling.2011.837">Keeling &#x00026; Bedwell 2011</a>]. It is also estimated that 10%-15% of human pathogenic variants are <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants [<a class="bk_pop" href="#ataxia-telangiectas.REF.mort.2008.1037">Mort et al 2008</a>], predicting investigation of many millions of potential drug candidates.</div></li></ul><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri"><u>ClinicalTrials.gov</u></a> for access to information on clinical studies for a wide range of diseases and conditions.</p></div><div id="ataxia-telangiectas.Other"><h3>Other</h3><p>Any child younger than age five years with malignancy should be evaluated for A-T before starting chemotherapy and/or radiotherapy since conventional doses of either can be fatal in A-T.</p></div></div><div id="ataxia-telangiectas.Genetic_Counseling"><h2 id="_ataxia-telangiectas_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="ataxia-telangiectas.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Ataxia-telangiectasia (A-T) is inherited an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="ataxia-telangiectas.Risk_to_Family_Membe"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>ATM</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are at increased risk for cancer and coronary artery disease [<a class="bk_pop" href="#ataxia-telangiectas.REF.concannon.2002.89">Concannon 2002</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.spring.2002.185">Spring et al 2002</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.van_os.2016.105">van Os et al 2016</a>] (see Clinical Description, <a href="#ataxia-telangiectas.Heterozygotes">Heterozygotes</a>).</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% risk of being affected, a 50% risk of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% risk of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are at increased risk for cancer and coronary artery disease [<a class="bk_pop" href="#ataxia-telangiectas.REF.concannon.2002.89">Concannon 2002</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.spring.2002.185">Spring et al 2002</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.van_os.2016.105">van Os et al 2016</a>] (see Clinical Description, <a href="#ataxia-telangiectas.Heterozygotes">Heterozygotes</a>).</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Although most individuals with A-T do not reproduce, exceptions have been reported [<a class="bk_pop" href="#ataxia-telangiectas.REF.stankovic.1998.334">Stankovic et al 1998</a>; <a class="bk_pop" href="#ataxia-telangiectas.REF.byrd.2012.262">Byrd et al 2012</a>; <a class="bk_pop" href="#ataxia-telangiectas.REF.dawson.2015.1937">Dawson et al 2015</a>; Blancato et al, unpublished].</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of an <i>ATM</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="ataxia-telangiectas.Carrier_Heterozygote"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>ATM</i> pathogenic variants in the family.</p></div><div id="ataxia-telangiectas.Related_Genetic_Coun"><h3>Related Genetic Counseling Issues</h3><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are carriers or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="ataxia-telangiectas.Prenatal_Testing_and"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>ATM</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk for A-T and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Note: Prenatal diagnosis by chromosomal breakage studies or by radio-resistant DNA synthesis (RDS) has proven unreliable in at least three instances [Author, unpublished] and should be avoided in favor of <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div></div><div id="ataxia-telangiectas.Resources"><h2 id="_ataxia-telangiectas_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>A-T Children's Project</b></div><div>5300 West Hillsboro Boulevard</div><div>#105</div><div>Coconut Creek FL 33073</div><div><b>Phone:</b> 800-543-5728 (toll-free); 954-481-6611</div><div><b>Fax:</b> 954-725-1153</div><div><b>Email:</b> info@atcp.org</div><div><a href="http://www.communityatcp.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.communityatcp.org</a></div></li><li class="half_rhythm"><div><b>National Cancer Institute (NCI)</b></div><div>6116 Executive Boulevard</div><div>Suite 300</div><div>Bethesda MD 20892-8322</div><div><b>Phone:</b> 800-422-6237 (toll-free)</div><div><b>Email:</b> cancergovstaff@mail.nih.gov</div><div><a href="http://www.cancer.gov/cancertopics/factsheet/Risk/ataxia" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Ataxia-Telangiectasia</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="https://ghr.nlm.nih.gov/condition/ataxia-telangiectasia" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Ataxia-telangiectasia</a></div></li><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22198/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Ataxia-telangiectasia</a></div></li><li class="half_rhythm"><div><b>National Ataxia Foundation</b></div><div>2600 Fernbrook Lane</div><div>Suite 119</div><div>Minneapolis MN 55447</div><div><b>Phone:</b> 763-553-0020</div><div><b>Email:</b> naf@ataxia.org</div><div><a href="http://www.ataxia.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ataxia.org</a></div></li><li class="half_rhythm"><div><b>European Society for Immunodeficiencies (ESID) Registry</b></div><div>Dr. Gerhard Kindle</div><div>University Medical Center Freiburg Centre of Chronic Immunodeficiency</div><div>Engesserstr. 4</div><div>79106 Freiburg </div><div>Germany</div><div><b>Phone:</b> 49-761-270-34450</div><div><b>Email:</b> esid-registry@uniklinik-freiburg.de</div><div><a href="http://esid.org/Working-Parties/Registry" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ESID Registry</a></div></li><li class="half_rhythm"><div><b>Prospective Registry of MultiPlex Testing (PROMPT)</b></div><div><i>PROMPT is an online research registry for patients and families who have undergone multiplex genetic testing and were found to have a genetic variation which may be linked to an increased risk of having cancer.</i></div><div><a href="https://connect.patientcrossroads.org/?org=prompt" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PROMPT</a></div></li></ul></div><div id="ataxia-telangiectas.Molecular_Genetics"><h2 id="_ataxia-telangiectas_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="ataxia-telangiectas.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Ataxia-Telangiectasia: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK26468/table/ataxia-telangiectas.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ataxia-telangiectas.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_ataxia-telangiectas.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_ataxia-telangiectas.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_ataxia-telangiectas.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_ataxia-telangiectas.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_ataxia-telangiectas.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_ataxia-telangiectas.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_ataxia-telangiectas.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/472" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ATM</i></a></td><td headers="hd_b_ataxia-telangiectas.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=472" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">11q22<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_ataxia-telangiectas.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q13315" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Serine-protein kinase ATM</a></td><td headers="hd_b_ataxia-telangiectas.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.lovd.nl/ATM" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Ataxia Telangiectasia Mutated (ATM) @ LOVD</a></td><td headers="hd_b_ataxia-telangiectas.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ATM" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ATM</a></td><td headers="hd_b_ataxia-telangiectas.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ATM[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ATM</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="ataxia-telangiectas.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="ataxia-telangiectas.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Ataxia-Telangiectasia (<a href="/omim/208900,607585" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK26468/table/ataxia-telangiectas.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ataxia-telangiectas.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/208900" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">208900</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ATAXIA-TELANGIECTASIA; AT</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/607585" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">607585</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ATAXIA-TELANGIECTASIA MUTATED GENE; ATM</td></tr></tbody></table></div></div><p><b>Gene structure.</b> The normal <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000051.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000051.3</a>) has 63 exons, 62 of which are coding (the transcription start (ATG) is in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2), and 13-kb <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a>.</p><p><b>Pathogenic variants.</b> More than 800 unique pathogenic variants are known (see <a class="figpopup" href="/books/NBK26468/table/ataxia-telangiectas.T.selected_atm_patho/?report=objectonly" target="object" rid-figpopup="figataxiatelangiectasTselectedatmpatho" rid-ob="figobataxiatelangiectasTselectedatmpatho">Table 2</a> and <a href="/books/NBK26468/bin/ataxia-telangiectas-Table3.pdf">Table 3</a> [pdf]). Although a few population-specific pathogenic variants have been identified, most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals in North America inherit different pathogenic variants from each parent; that is, they are compound heterozygotes [<a class="bk_pop" href="#ataxia-telangiectas.REF.concannon.1997.100">Concannon &#x00026; Gatti 1997</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.gatti.2001">Gatti 2001</a>].</p><div id="ataxia-telangiectas.T.selected_atm_patho" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Selected <i>ATM</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK26468/table/ataxia-telangiectas.T.selected_atm_patho/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ataxia-telangiectas.T.selected_atm_patho_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1A&#x0003e;G</td><td headers="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Met1Val</td><td headers="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_3" rowspan="11" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/71902539" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000051<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/71902540" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000042<wbr style="display:inline-block"></wbr>​.3</a></td></tr><tr><td headers="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.103C&#x0003e;T</td><td headers="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg35Ter</td></tr><tr><td headers="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3894dupT</td><td headers="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala1299CysfsTer3</td></tr><tr><td headers="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.5763-1050A&#x0003e;G<br />(5762ins137)</td><td headers="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 2</td></tr><tr><td headers="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.6154G&#x0003e;A&#x000a0;<sup>3</sup></td><td headers="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu2052Lys</td></tr><tr><td headers="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.6200C&#x0003e;A</td><td headers="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala2067Asp</td></tr><tr><td headers="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.6679C&#x0003e;T</td><td headers="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg2227Cys</td></tr><tr><td headers="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.7271T&#x0003e;G</td><td headers="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val2424Gly</td></tr><tr><td headers="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.7886_7890delTATTA</td><td headers="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile2629SerfsTer25</td></tr><tr><td headers="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.8147T&#x0003e;C</td><td headers="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val2716Ala&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.8494C&#x0003e;T</td><td headers="hd_h_ataxia-telangiectas.T.selected_atm_patho_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg2832Cys</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="ataxia-telangiectas.TF.2.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="ataxia-telangiectas.TF.2.2"><p class="no_margin">Activates a cryptic <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> resulting in a 137-bp <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> and an unstable protein [<a class="bk_pop" href="#ataxia-telangiectas.REF.mcconville.1996.320">McConville et al 1996</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.stankovic.1998.334">Stankovic et al 1998</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.stewart.2001.30133">Stewart et al 2001</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.sutton.2004.891">Sutton et al 2004</a>]</p></div></dd><dt>3. </dt><dd><div id="ataxia-telangiectas.TF.2.3"><p class="no_margin">Causes abnormal <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a></p></div></dd><dt>4. </dt><dd><div id="ataxia-telangiectas.TF.2.4"><p class="no_margin"><a class="bk_pop" href="#ataxia-telangiectas.REF.saunderspullman.2009.414">Saunders-Pullman &#x00026; Gatti [2009]</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.verhagen.2009.430">Verhagen et al [2009]</a></p></div></dd></dl></div></div></div><p>For information about founder variants described in specific populations, see <a href="/books/NBK26468/bin/ataxia-telangiectas-Table3.pdf">Table 3</a> (pdf).</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The normal serine/threonine protein kinase ATM has 3056 amino acids. It is activated by double-stranded DNA breaks, coordinates cell-cycle checkpoints prior to repair, attaches near damage sites, and recruits other repair proteins to damaged sites [<a class="bk_pop" href="#ataxia-telangiectas.REF.lavin.2008.1061">Lavin et al 2008</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.lavin.2013.1650">Lavin 2013</a>].</p><ul><li class="half_rhythm"><div>Domains for: PI3 kinase, FAT, leucine zipper, FATC, p53 binding</div></li><li class="half_rhythm"><div>Binding sites for: c-abl, p53, Bloom's protein</div></li><li class="half_rhythm"><div>Other homologies: DNA-PK, ATR/MEC1, MEI41, Rad3, TEL1, FRAP</div></li><li class="half_rhythm"><div>Substrates for phosphorylation: &#x0003e;700, including p53, Chk2, MDM2, 53BP1, SMC1, BRCA1, FANCD2, H2AX, c-abl, nibrin, Mre11, KAP1 [<a class="bk_pop" href="#ataxia-telangiectas.REF.linding.2007.1415">Linding et al 2007</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.matsuoka.2007.1160">Matsuoka et al 2007</a>].</div></li></ul><p>A growing body of evidence also suggests that ATM kinase deficiency and ATM-specific small molecule inhibitors suppress HIV-1 replication and infection in bench experiments [<a class="bk_pop" href="#ataxia-telangiectas.REF.lau.2005.493">Lau et al 2005</a>, <a class="bk_pop" href="#ataxia-telangiectas.REF.ariumi.2006.2445">Ariumi &#x00026; Trono 2006</a>]; this would probably also apply to other retroviral infections and, eventually, could provide some insight as to a genetic selective advantage for ATM heterozygosity and possibly even for homozygosity in the general population.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Most <i>ATM</i> pathogenic variants result in absence of ATM protein. Serine-protein kinase ATM is absent on immunoblotting in 95% of individuals with A-T. ATM <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> is present in more than 99% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals; however, the quantity of mRNA from each <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> may not be equal.</p><p>About 1% of individuals with A-T have pathogenic variants that permit normal expression of ATM protein, but the protein is lacking in kinase activity (so-called "kinase-dead" ATM protein).</p><p>In vitro functional assays showed that selected <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> pathogenic variants result in an ATM protein that interferes with the function of normal ATM protein (i.e., a <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> or <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> effect) [<a class="bk_pop" href="#ataxia-telangiectas.REF.barone.2009.1222">Barone et al 2009</a>]. It has been proposed that such effects play a role in the development of breast cancer in <i>ATM</i> heterozygotes [<a class="bk_pop" href="#ataxia-telangiectas.REF.scott.2002.925">Scott et al 2002</a>].</p></div><div id="ataxia-telangiectas.References"><h2 id="_ataxia-telangiectas_References_">References</h2><div id="ataxia-telangiectas.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.almaawali.2012.1121">Al-Maawali A, Blaser S, Yoon G. Diagnostic approach to childhood-onset cerebellar atrophy: a 10-year retrospective study of 300 patients. <span><span class="ref-journal">J Child Neurol. </span>2012;<span class="ref-vol">27</span>:1121–32.</span> [<a href="/pmc/articles/PMC3743560/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3743560</span></a>] [<a href="/pubmed/22764178" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22764178</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.ambrose.2007.2154">Ambrose M, Goldstine JV, Gatti RA. Intrinsic mitochondrial dysfunction in ATM-deficient lymphoblastoid cells. <span><span class="ref-journal">Hum Mol Genet. </span>2007;<span class="ref-vol">16</span>:2154–64.</span> [<a href="/pubmed/17606465" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17606465</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.ariumi.2006.2445">Ariumi Y, Trono D. Ataxia-Telangiectasia-Mutated (ATM) protein can enhance human immunodeficiency virus type 1 replication by stimulating Rev function. <span><span class="ref-journal">J Virol. </span>2006;<span class="ref-vol">80</span>:2445–52.</span> [<a href="/pmc/articles/PMC1395391/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1395391</span></a>] [<a href="/pubmed/16474151" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16474151</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.barone.2009.1222">Barone G, Groom A, Reiman A, Srinivasan V, Byrd PJ, Taylor AM. Modeling ATM mutant proteins from missense changes confirms retained kinase activity. <span><span class="ref-journal">Hum Mutat. </span>2009;<span class="ref-vol">30</span>:1222–30.</span> [<a href="/pubmed/19431188" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19431188</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.bernstein.2003.1513">Bernstein JL, Bernstein L, Thompson WD, Lynch CF, Malone KE, Teitelbaum SL, Olsen JH, Anton-Culver H, Boice JD, Rosenstein BS, B&#x000f8;rresen-Dale AL, Gatti RA, Concannon P, Haile RW., WECARE Study Collaborative Group.  ATM variants 7271T&#x0003e;G and IVS10-6T&#x0003e;G among women with unilateral and bilateral breast cancer. <span><span class="ref-journal">Br J Cancer. </span>2003;<span class="ref-vol">89</span>:1513–6.</span> [<a href="/pmc/articles/PMC2394328/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2394328</span></a>] [<a href="/pubmed/14562025" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14562025</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.bernstein.2006.1122">Bernstein JL, Teraoka S, Southey MC, Jenkins MA, Andrulis IL, Knight JA, John EM, Lapinski R, Wolitzer AL, Whittemore AS, West D, Seminara D, Olson ER, Spurdle AB, Chenevix-Trench G, Giles GG, Hopper JL, Concannon P. Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T&#x0003e;G and c.1066-6T&#x0003e;G (IVS10-6T&#x0003e;G) from the Breast Cancer Family Registry. <span><span class="ref-journal">Hum Mutat. </span>2006;<span class="ref-vol">27</span>:1122–8.</span> [<a href="/pubmed/16958054" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16958054</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.bhatt.2015.565">Bhatt JM, Bush A, van Gerven M, Nissenkorn A, Renke M, Yarlett L, Taylor M, Tonia T, Warris A, Zielen S, Zinna S, Merkus PJ., European Respiratory Society.  ERS statement on the multidisciplinary respiratory management of ataxia telangiectasia. <span><span class="ref-journal">Eur Respir Rev. </span>2015;<span class="ref-vol">24</span>:565–81.</span> [<a href="/pubmed/26621971" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26621971</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.bodensteiner.1980.464">Bodensteiner JB, Goldlum RM, Goldman AS. Progressive dystonia masking ataxia in ataxia-telangiectasia. <span><span class="ref-journal">Arch Neurol. </span>1980;<span class="ref-vol">37</span>:464–5.</span> [<a href="/pubmed/7387499" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7387499</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.boder.1985">Boder E. Ataxia-telangiectasia: an overview. In: RA Gatti, M Swift, eds. <em>Ataxia-Telangiectasia: Genetics, Neuropathy, and Immunology of a Degenerative Disease of Childhood.</em> New York, NY: Alan R Liss; 1985:1-63.</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.bretsky.2003.733">Bretsky P, Haiman CA, Gilad S, Yahalom J, Grossman A, Paglin S, Van Den Berg D, Kolonel LN, Skaliter R, Henderson BE. The relationship between twenty missense ATM variants and breast cancer risk: the multiethnic cohort. <span><span class="ref-journal">Cancer Epidemiol Biomarkers Prev. </span>2003;<span class="ref-vol">12</span>:733–8.</span> [<a href="/pubmed/12917204" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12917204</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.broccoletti.2008.223">Broccoletti T, Del Giudice E, Amorosi S, Russo I, Di Bonito M, Imperati F, Romano A, Pignata C. Steroid-induced improvement of neurological signs in ataxia-telangiectasia patients. <span><span class="ref-journal">Eur J Neurol. </span>2008;<span class="ref-vol">15</span>:223–8.</span> [<a href="/pubmed/18290844" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18290844</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.brown.2016">Brown C, Martin N, Lee D, Nelson R, Bogdanova N, Doerk T, Gatti RA (2016) RAD50 deficiency with leukemia, cellular radiosensitivity, and a heterozygous NBS mutation. In review.</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.buoni.2006.1479">Buoni S, Zannolli R, Sorrentino L, Fois A. Betamethasone and improvement of neurological symptoms in ataxia-telangiectasia. <span><span class="ref-journal">Arch Neurol. </span>2006;<span class="ref-vol">63</span>:1479–82.</span> [<a href="/pubmed/17030666" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17030666</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.byrd.2012.262">Byrd PJ, Srinivasan V, Last JI, Smith A, Biggs P, Carner EF, Exley A, Abson C, Stewart GS, Izatt L, Taylor AM. Severe reaction to radiotherapy for breast cancer as the presenting feature of ataxia telangiectasia. <span><span class="ref-journal">Brit J Cancer. </span>2012;<span class="ref-vol">106</span>:262–68.</span> [<a href="/pmc/articles/PMC3261689/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3261689</span></a>] [<a href="/pubmed/22146522" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22146522</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.cavalieri.2008.10">Cavalieri S, Funaro A, Pappi P, Migone N, Gatti RA, Brusco A. Large genomic mutations within the ATM gene detected by MLPA, including a duplication of 41 kb from exon 4 to 20. <span><span class="ref-journal">Ann Hum Genet. </span>2008;<span class="ref-vol">72</span>:10–8.</span> [<a href="/pubmed/17910737" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17910737</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.charlesworth.2013.1148">Charlesworth G, Mohire MD, Schneider SSA, Stamelou M, Wood NW, Bhatia K. Ataxia telangiectasia presenting as dopa-responsive cervival dystonia. <span><span class="ref-journal">Neurology. </span>2013;<span class="ref-vol">81</span>:1148–51.</span> [<a href="/pmc/articles/PMC3795596/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3795596</span></a>] [<a href="/pubmed/23946315" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23946315</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.chun.2004.1187">Chun HH, Gatti RA. Ataxia-telangiectasia, an evolving phenotype. <span><span class="ref-journal">DNA Repair (Amst). </span>2004;<span class="ref-vol">3</span>:1187–96.</span> [<a href="/pubmed/15279807" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15279807</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.chun.2003.437">Chun HH, Sun X, Nahas SA, Teraoka S, Lai CH, Concannon P, Gatti RA. Improved diagnostic testing for ataxia-telangiectasia by immunoblotting of nuclear lysates for ATM protein expression. <span><span class="ref-journal">Mol Genet Metab. </span>2003;<span class="ref-vol">80</span>:437–43.</span> [<a href="/pubmed/14654357" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14654357</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.concannon.2002.89">Concannon P. ATM heterozygosity and cancer risk. <span><span class="ref-journal">Nat Genet. </span>2002;<span class="ref-vol">32</span>:89–90.</span> [<a href="/pubmed/12205473" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12205473</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.concannon.1997.100">Concannon P, Gatti RA. Diversity of ATM gene mutations detected in patients with ataxia-telangiectasia. <span><span class="ref-journal">Hum Mutat. </span>1997;<span class="ref-vol">10</span>:100–7.</span> [<a href="/pubmed/9259193" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9259193</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.concannon.2008.6486">Concannon P, Haile RW, B&#x000f8;rresen-Dale AL, Rosenstein BS, Gatti RA, Teraoka SN, Diep TA, Jansen L, Atencio DP, Langholz B, Capanu M, Liang X, Begg CB, Thomas DC, Bernstein L, Olsen JH, Malone KE, Lynch CF, Anton-Culver H, Bernstein JL, et al.  Variants in the ATM gene associated with a reduced risk of contralateral breast cancer. <span><span class="ref-journal">Cancer Res. </span>2008;<span class="ref-vol">68</span>:6486–91.</span> [<a href="/pmc/articles/PMC2562548/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2562548</span></a>] [<a href="/pubmed/18701470" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18701470</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.crawford.2006.610">Crawford TO, Skolasky R, Fernandez R, Rosquist KJ, Lederman HM. Survival probability in ataxia Telangiectasia. <span><span class="ref-journal">Arch Dis Child. </span>2006;<span class="ref-vol">91</span>:610–1.</span> [<a href="/pmc/articles/PMC2082822/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2082822</span></a>] [<a href="/pubmed/16790721" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16790721</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.curry.1989.270">Curry CJ, O'Lague P, Tsai J, Hutchison HT, Jaspers NG, Wara D, Gatti RA. ATFresno: a phenotype linking ataxia-telangiectasia with the Nijmegen breakage syndrome. <span><span class="ref-journal">Am J Hum Genet. </span>1989;<span class="ref-vol">45</span>:270–5.</span> [<a href="/pmc/articles/PMC1683342/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1683342</span></a>] [<a href="/pubmed/2491181" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2491181</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.date.2001.184">Date H, Onodera O, Tanaka H, Iwabuchi K, Uekawa K, Igarashi S, Koike R, Hiroi T, Yuasa T, Awaya Y, Sakai T, Takahashi T, Nagatomo H, Sekijima Y, Kawachi I, Takiyama Y, Nishizawa M, Fukuhara N, Saito K, Sugano S, Tsuji S. Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is caused by mutations in a new HIT superfamily gene. <span><span class="ref-journal">Nat Genet. </span>2001;<span class="ref-vol">29</span>:184–8.</span> [<a href="/pubmed/11586299" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11586299</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.dawson.2015.1937">Dawson AJ, Marles S, Tomiuk M, Riordan D, Gatti RA. Ataxia-telangiectasia with female fertility. <span><span class="ref-journal">Am J Med Genet A. </span>2015;<span class="ref-vol">167A</span>:1937–9.</span> [<a href="/pubmed/25914063" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25914063</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.devgan.2011.1500">Devgan SS, Sanal O, Doil C, Nakamura K, Nahas SA, Pettijohn K, Bartek J, Lukas C, Lukas J, Gatti RA. Homozygous deficiency of ubiquitin-ligase ring-finger protein RNF168 mimics the radiosensitivity syndrome of ataxia-telangiectasia. <span><span class="ref-journal">Cell Death Differ. </span>2011;<span class="ref-vol">18</span>:1500–6.</span> [<a href="/pmc/articles/PMC3178430/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3178430</span></a>] [<a href="/pubmed/21394101" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21394101</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.d_rk.2004.272">D&#x000f6;rk T, Bendix-Waltes R, Wegner RD, Stumm M. Slow progression of ataxia-telangiectasia with double missense and in frame splice mutations. <span><span class="ref-journal">Am J Med Genet A. </span>2004;<span class="ref-vol">126A</span>:272–7.</span> [<a href="/pubmed/15054841" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15054841</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.du.2009.2285">Du L, Damoiseaux R, Nahas S, Gao K, Hu H, Pollard JM, Goldstine J, Jung ME, Henning SM, Bertoni C, Gatti RA. Nonaminoglycoside compounds induce readthrough of nonsense mutations. <span><span class="ref-journal">J Exp Med. </span>2009;<span class="ref-vol">206</span>:2285–97.</span> [<a href="/pmc/articles/PMC2757881/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2757881</span></a>] [<a href="/pubmed/19770270" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19770270</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.du.2009.116">Du L, Gatti RA. Progress toward therapy with antisense-mediated splicing modulation. <span><span class="ref-journal">Curr Opin Mol Ther. </span>2009;<span class="ref-vol">11</span>:116–23.</span> [<a href="/pmc/articles/PMC2753608/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2753608</span></a>] [<a href="/pubmed/19330717" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19330717</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.du.2013.1653">Du L, Jung ME, Damoiseaux R, Completo G, Fike F, Ku JM, Nahas S, Piao C, Hu H, Gatti RA. A new series of small molecular weight compounds induce read through of all three types of nonsense mutations in the ATM gene. <span><span class="ref-journal">Mol Ther. </span>2013;<span class="ref-vol">21</span>:1653–60.</span> [<a href="/pmc/articles/PMC3776636/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3776636</span></a>] [<a href="/pubmed/23774824" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23774824</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.du.2007.6007">Du L, Pollard J, Gatti RA. Correction of prototypic ATM splicing mutation and aberrant ATM function with antisense morpholino oligonucleotides. <span><span class="ref-journal">PNAS. </span>2007;<span class="ref-vol">104</span>:6007–12.</span> [<a href="/pmc/articles/PMC1832221/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1832221</span></a>] [<a href="/pubmed/17389389" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17389389</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.eclache.2004.72">Eclache V, Caulet-Maugendre S, Poirel HA, Djemai M, Robert J, Lejeune F, Raphael M. Cryptic deletion involving the ATM locus at 11q22.3 approximately q23.1 in B-cell chronic lymphocytic leukemia and related disorders. <span><span class="ref-journal">Cancer Genet Cytogenet. </span>2004;<span class="ref-vol">152</span>:72–6.</span> [<a href="/pubmed/15193446" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15193446</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.farr.2002.891">Farr AK, Shalev B, Crawford TO, Lederman HM, Winkelstein JA, Repka MX. Ocular manifestations of ataxia-telangiectasia. <span><span class="ref-journal">Am J Ophthalmol. </span>2002;<span class="ref-vol">134</span>:891–6.</span> [<a href="/pubmed/12470759" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12470759</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.fernandez.2005.134">Fernandez AM, Carro EM, Lopez-Lopez C, Torres-Aleman I. Insulin-like growth factor I treatment for cerebellar ataxia: addressing a common pathway in the pathological cascade? <span><span class="ref-journal">Brain Res Brain Res Rev. </span>2005;<span class="ref-vol">50</span>:134–41.</span> [<a href="/pubmed/15950289" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15950289</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.gatti.2001">Gatti RA. Ataxia-telangiectasia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. <em>The Metabolic and Molecular Bases of Inherited Disease</em>. 8 ed. New York, NY: McGraw-Hill. 2001:705-32.</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.gatti.1985">Gatti RA. Concluding discussion. In: Gatti RA, Swift M, eds. <em>Ataxia-Telangiectasia: Genetics, Neuropathology, and Immunology of a Degenerative Disease of Childhood</em>. New York: Alan R Liss; 1985:357-59.</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.gatti.2012.33">Gatti RA. SMRT compounds correct nonsense mutations in primary immunodeficiency and other genetic models. <span><span class="ref-journal">Ann N Y Acad Sci. </span>2012;<span class="ref-vol">1250</span>:33–40.</span> [<a href="/pmc/articles/PMC3754805/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3754805</span></a>] [<a href="/pubmed/22364446" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22364446</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.gatti.2007.87">Gatti RA, Boder E, Good RA. Immunodeficiency, radiosensitivity, and the XCIND syndrome. <span><span class="ref-journal">Immunol Res. </span>2007;<span class="ref-vol">38</span>:87–101.</span> [<a href="/pubmed/17917014" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17917014</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.gatti.2009.653">Gatti RA, Perlman S. A proposed bailout for A-T patients? <span><span class="ref-journal">Eur J Neurol. </span>2009;<span class="ref-vol">16</span>:653–5.</span> [<a href="/pmc/articles/PMC3242728/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3242728</span></a>] [<a href="/pubmed/19459929" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19459929</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.gatti.1999.419">Gatti RA, Tward A, Concannon P. Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. <span><span class="ref-journal">Mol Genet Metab. </span>1999;<span class="ref-vol">68</span>:419–23.</span> [<a href="/pubmed/10607471" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10607471</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.gilad.1998.551">Gilad S, Chessa L, Khosravi R, Russell P, Galanty Y, Piane M, Gatti RA, Jorgensen TJ, Shiloh Y, Bar-Shira A. Genotype-phenotype relationships in ataxia-telangiectasia and variants. <span><span class="ref-journal">Am J Hum Genet. </span>1998;<span class="ref-vol">62</span>:551–61.</span> [<a href="/pmc/articles/PMC1376949/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1376949</span></a>] [<a href="/pubmed/9497252" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9497252</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.goyal.2002.187">Goyal V, Behari M. Dystonia as presenting manifestation of ataxia telangiectasia: a case report. <span><span class="ref-journal">Neurol India. </span>2002;<span class="ref-vol">50</span>:187–9.</span> [<a href="/pubmed/12134185" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12134185</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.hiel.2006.346">Hiel JA, van Engelen BG, Weemaes CM, Broeks A, Verrips A, ter Laak H, Vingerhoets HM, van den Heuvel LP, Lammens M, Gabreels FJ, Last JI, Taylor AM. Distal spinal muscular atrophy as a major feature in adult-onset ataxia telangiectasia. <span><span class="ref-journal">Neurology. </span>2006;<span class="ref-vol">67</span>:346–9.</span> [<a href="/pubmed/16864838" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16864838</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.hu.2008.540">Hu H, Gatti RA. New approaches to treatment of primary immune deficiencies: fixing mutations with chemicals. <span><span class="ref-journal">Curr Opin Allergy Clin Immunol. </span>2008;<span class="ref-vol">8</span>:540–6.</span> [<a href="/pmc/articles/PMC2686128/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2686128</span></a>] [<a href="/pubmed/18978469" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18978469</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.jung.2011.5842">Jung ME, Ku JM, Du L, Hu H, Gatti RA. Synthesis and evaluation of compounds that induce readthrough of premature termination codons. <span><span class="ref-journal">Bioorg Med Chem Lett. </span>2011;<span class="ref-vol">21</span>:5842–8.</span> [<a href="/pubmed/21873052" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21873052</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.kayali.2012.4007">Kayali R, Ku JM, Khitrov G, Jung ME, Prikhodko O, Bertoni C. Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. <span><span class="ref-journal">Hum Mol Genet. </span>2012;<span class="ref-vol">21</span>:4007–20.</span> [<a href="/pmc/articles/PMC3607466/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3607466</span></a>] [<a href="/pubmed/22692682" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22692682</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.keeling.2011.837">Keeling KM, Bedwell DM. Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases. <span><span class="ref-journal">Wiley Interdiscip Rev RNA. </span>2011;<span class="ref-vol">2</span>:837–52.</span> [<a href="/pmc/articles/PMC3188951/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3188951</span></a>] [<a href="/pubmed/21976286" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21976286</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.kuschal.2013.19483">Kuschal C, DiGiovanna JJ, Khan SG, Gatti RA, Kraemer KH. Repair of UV photolesions in xeroderma pigmentosum group C cells induced by translational read through of premature termination codons. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2013;<span class="ref-vol">110</span>:19483–8.</span> [<a href="/pmc/articles/PMC3845163/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3845163</span></a>] [<a href="/pubmed/24218596" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24218596</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.lagiertourenne.2008.661">Lagier-Tourenne C, Tazir M, Lopez LC, Quinzii CM, Assoum M, Drouot N, Busso C, Makri S, Ali-Pacha L, Benhassine T, Anheim M, Lynch DR, Thibault C, Plewniak F, Bianchetti L, Tranchant C, Poch O, DiMauro S, Mandel J-L, Barros MH, Hirano M, Koenig M. ADKC3, an ancestral kinase, is mutated in a form of recessive ataxia associated with Coenzyme Q<sub>10</sub> deficiency. <span><span class="ref-journal">Amer J Hum Genet. </span>2008;<span class="ref-vol">82</span>:661–72.</span> [<a href="/pmc/articles/PMC2427193/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2427193</span></a>] [<a href="/pubmed/18319074" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18319074</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.lai.2004.15676">Lai CH, Chun HH, Nahas SA, Mitui M, Gamo KM, Du L, Gatti RA. Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>2004;<span class="ref-vol">101</span>:15676–81.</span> [<a href="/pmc/articles/PMC524838/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC524838</span></a>] [<a href="/pubmed/15498871" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15498871</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.lau.2005.493">Lau A, Swinbank KM, Ahmed PS, Taylor DL, Jackson SP, Smith GC, O'Connor MJ. Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase. <span><span class="ref-journal">Nat Cell Biol. </span>2005;<span class="ref-vol">7</span>:493–500.</span> [<a href="/pubmed/15834407" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15834407</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.lavin.2008.1061">Lavin MF, Gueven N, Grattan-Smith P. Defective responses to DNA single- and double-strand breaks in spinocerebellar ataxia. <span><span class="ref-journal">DNA Repair (Amst). </span>2008;<span class="ref-vol">7</span>:1061–76.</span> [<a href="/pubmed/18467193" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18467193</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.lavin.2015.2877">Lavin MF, Kozlov S, Gatei M, Kijas AW. ATM-dependent phosphorylation of all three members of the MRN complex: from sensor to adaptor. <span><span class="ref-journal">Biomolecules. </span>2015;<span class="ref-vol">5</span>:2877–902.</span> [<a href="/pmc/articles/PMC4693261/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4693261</span></a>] [<a href="/pubmed/26512707" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26512707</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.lavin.2013.1650">Lavin MF. Generating SM(a)RTer compounds for translation termination suppression in A-T and other genetic disorders. <span><span class="ref-journal">Mol Ther. </span>2013;<span class="ref-vol">21</span>:1650–2.</span> [<a href="/pmc/articles/PMC3776641/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3776641</span></a>] [<a href="/pubmed/24008619" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24008619</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.leftongreif.2000.225">Lefton-Greif MA, Crawford TO, Winkelstein JA, Loughlin GM, Koerner CB, Zahurak M, Lederman HM. Oropharyngeal dysphagia and aspiration in patients with ataxia-telangiectasia. <span><span class="ref-journal">J Pediatr. </span>2000;<span class="ref-vol">136</span>:225–31.</span> [<a href="/pubmed/10657830" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10657830</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.leuzzi.2015.e98">Leuzzi V, Micheli R, D'Agnano D, Molinaro A, Venturi T, Plebani A, Soresina A, Marini M, Ferremi Leali P, Quinti I, Pietrogrande MC, Finocchi A, Fazzi E, Chessa L, Magnani M. Positive effect of erythrocyte-delivered dexamethasone in ataxia-telangiectasia. <span><span class="ref-journal">Neurol Neuroimmunol Neuroinflamm. </span>2015;<span class="ref-vol">2</span>:e98.</span> [<a href="/pmc/articles/PMC4396528/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4396528</span></a>] [<a href="/pubmed/25884015" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25884015</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.liberzon.2004.161">Liberzon E, Avigad S, Stark B, Zilberstein J, Freedman L, Gorfine M, Gavriel H, Cohen IJ, Goshen Y, Yaniv I, Zaizov R. Germ-line ATM gene alterations are associated with susceptibility to sporadic T-cell acute lymphoblastic leukemia in children. <span><span class="ref-journal">Genes Chromosomes Cancer. </span>2004;<span class="ref-vol">39</span>:161–6.</span> [<a href="/pubmed/14695997" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14695997</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.lin.2014.119">Lin DD, M, Barker PB, Lederman HM, Crawford TO. Cerebral abnormalities in adults with ataxia-telangiectasia. <span><span class="ref-journal">Am J Neuroradiol. </span>2014;<span class="ref-vol">35</span>:119–123.</span> [<a href="/pmc/articles/PMC4106125/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4106125</span></a>] [<a href="/pubmed/23886747" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23886747</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.linding.2007.1415">Linding R, Jensen LJ, Ostheimer GJ, van Vugt MA, J&#x000f8;rgensen C, Miron IM, Diella F, Colwill K, Taylor L, Elder K, Metalnikov P, Nguyen V, Pasculescu A, Jin J, Park JG, Samson LD, Woodgett JR, Russell RB, Bork P, Yaffe MB, Pawson T. Systematic discovery of in vivo phosphorylation networks. <span><span class="ref-journal">Cell. </span>2007;<span class="ref-vol">129</span>:1415–26.</span> [<a href="/pmc/articles/PMC2692296/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2692296</span></a>] [<a href="/pubmed/17570479" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17570479</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.lockman.2012.256">Lockman JL, Iskander AJ, Bembea M, Crawford TO, Lederman HM, McGrath-Morrow S, Easley RB. Anesthetic and perioperative risk in the patient with ataxia-telangiectasia. <span><span class="ref-journal">Paediatr Anaesth. </span>2012;<span class="ref-vol">22</span>:256–62.</span> [<a href="/pubmed/22098343" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22098343</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.loudon.2013.79">Loudon JA. Repurposing Amlexanox as a "Run the red light cure all" with read-through &#x02013; a "no-nonsense" approach to personalized medicine. <span><span class="ref-journal">J Bioanal Biomed. </span>2013;<span class="ref-vol">5</span>:79–96.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.mallott.2013.540">Mallott J, Kwan A, Church J, Gonzalez-Espinosa D, Lorey F, Tang LF, Sunderam U, Rana S, Srinivasan R, Brenner SE, Puck J. Newborn screening for SCID identifies patients with ataxia telangiectasia. <span><span class="ref-journal">J Clin Immunol. </span>2013;<span class="ref-vol">33</span>:540–9.</span> [<a href="/pmc/articles/PMC3591536/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3591536</span></a>] [<a href="/pubmed/23264026" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23264026</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.matsuoka.2007.1160">Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3rd, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y, Shiloh Y, Gygi SP, Elledge SJ. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. <span><span class="ref-journal">Science. </span>2007;<span class="ref-vol">316</span>:1160–6.</span> [<a href="/pubmed/17525332" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17525332</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.mcconville.1996.320">McConville CM, Stankovic T, Byrd PJ, McGuire GM, Yao QY, Lennox GG, Taylor MR. Mutations associated with variant phenotypes in ataxia-telangiectasia. <span><span class="ref-journal">Am J Hum Genet. </span>1996;<span class="ref-vol">59</span>:320–30.</span> [<a href="/pmc/articles/PMC1914715/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1914715</span></a>] [<a href="/pubmed/8755918" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8755918</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.mcgrathmorrow.2008.59">McGrath-Morrow S, Lefton-Greif M, Rosquist K, Crawford T, Kelly A, Zeitlin P, Carson KA, Lederman HM. Pulmonary function in adolescents with ataxia telangiectasia. <span><span class="ref-journal">Pediatr Pulmonol. </span>2008;<span class="ref-vol">43</span>:59–66.</span> [<a href="/pubmed/18041755" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18041755</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.mitui.2009.12">Mitui M, Nahas SA, Du LT, Yang Z, Lai CH, Nakamura K, Arroyo S, Scott S, Purayidom A, Concannon P, Lavin M, Gatti RA. Functional and computational assessment of missense variants in the ATM gene: mutations with increased cancer risk. <span><span class="ref-journal">Hum Mutat. </span>2009;<span class="ref-vol">30</span>:12–21.</span> [<a href="/pmc/articles/PMC2776735/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2776735</span></a>] [<a href="/pubmed/18634022" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18634022</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.moreira.2001.189">Moreira MC, Barbot C, Tachi N, Kozuka N, Uchida E, Gibson T, Mendonca P, Costa M, Barros J, Yanagisawa T, Watanabe M, Ikeda Y, Aoki M, Nagata T, Coutinho P, Sequeiros J, Koenig M. The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn-finger protein aprataxin. <span><span class="ref-journal">Nat Genet. </span>2001;<span class="ref-vol">29</span>:189–93.</span> [<a href="/pubmed/11586300" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11586300</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.mort.2008.1037">Mort M, Ivanov D, Cooper DN, Chuzhanova NA. A meta-analysis of nonsense mutations causing human genetic disease. <span><span class="ref-journal">Hum Mutat. </span>2008;<span class="ref-vol">29</span>:1037–47.</span> [<a href="/pubmed/18454449" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18454449</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.nakamura.2014.332">Nakamura K, Fike F, Haghayegh S, Saunders-Pullman R, Dawson AJ, D&#x000f6;rk T, Gatti RA. A-TWinnipeg: Pathogenesis of rare ATM missense mutation c.6200C&#x0003e;A with decreased protein expression and downstream signaling, early-onset dystonia, cancer, and life-threatening radiotoxicity. <span><span class="ref-journal">Mol Genet Genomic Med. </span>2014;<span class="ref-vol">2</span>:332–40.</span> [<a href="/pmc/articles/PMC4113274/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4113274</span></a>] [<a href="/pubmed/25077176" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25077176</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.n_meth.2000.1320">N&#x000e9;meth AH, Bochukova E, Dunne E, Huson SM, Elston J, Hannan MA, Jackson M, Chapman CJ, Taylor AM. Autosomal recessive cerebellar ataxia with oculomotor apraxia (ataxia-telangiectasia-like syndrome) is linked to chromosome 9q34. <span><span class="ref-journal">Am J Hum Genet. </span>2000;<span class="ref-vol">67</span>:1320–6.</span> [<a href="/pmc/articles/PMC1288574/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1288574</span></a>] [<a href="/pubmed/11022012" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11022012</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.nissenkorn.2013.155">Nissenkorn A, Hassin-Baer S, Lerman SF, Levi YB, Tzadok M, Ben-Zeev B. Movement disorder in ataxia-telangiectasia: treatment with amantadine sulfate. <span><span class="ref-journal">J Child Neurol. </span>2013;<span class="ref-vol">28</span>:155–60.</span> [<a href="/pubmed/22550086" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22550086</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.nowakwegrzyn.2004.505">Nowak-Wegrzyn A, Crawford TO, Winkelstein JA, Carson KA, Lederman HM. Immunodeficiency and infections in ataxia-telangiectasia. <span><span class="ref-journal">J Pediatr. </span>2004;<span class="ref-vol">144</span>:505–11.</span> [<a href="/pubmed/15069401" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15069401</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.oguchi.2003.3622">Oguchi K, Takagi M, Tsuchida R, Taya Y, Ito E, Isoyama K, Ishii E, Zannini L, Delia D, Mizutani S. Missense mutation and defective function of ATM in a childhood acute leukemia patient with MLL gene rearrangement. <span><span class="ref-journal">Blood. </span>2003;<span class="ref-vol">101</span>:3622–7.</span> [<a href="/pubmed/12511424" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12511424</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.onodera.2006.361">Onodera O. Spinocerebellar ataxia with ocular motor apraxia and DNA repair. <span><span class="ref-journal">Neuropathology. </span>2006;<span class="ref-vol">26</span>:361–7.</span> [<a href="/pubmed/16961074" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16961074</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.pashankar.2006.156">Pashankar F, Singhal V, Akabogu I, Gatti RA, Goldman FD. Intact T cell responses in ataxia telangiectasia. <span><span class="ref-journal">Clin Immunol. </span>2006;<span class="ref-vol">120</span>:156–62.</span> [<a href="/pubmed/16762595" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16762595</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.perlman.2012.307">Perlman SL, Boder Deceased E, Sedgewick RP, Gatti RA. Ataxia-telangiectasia. <span><span class="ref-journal">Handb Clin Neurol. </span>2012;<span class="ref-vol">103</span>:307–32.</span> [<a href="/pubmed/21827897" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21827897</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.pillers.2015">Pillers DM, Shahi P, Bakhutashvili V, Brar S, Gatti R, Pattnaik BR. Variable read-through by small molecule drugs in Leber congenital amaurosis (LCA16) suggests need for personalized approach to read-through strategies. Poster session. Baltimore, MD: American Society of Human Genetics Meeting. 2015.</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.pitts.2001.1155">Pitts SA, Kullar HS, Stankovic T, Stewart GS, Last JI, Bedenham T, Armstrong SJ, Piane M, Chessa L, Taylor AM, Byrd PJ. hMRE11: genomic structure and a null mutation identified in a transcript protected from nonsense-mediated mRNA decay. <span><span class="ref-journal">Hum Mol Genet. </span>2001;<span class="ref-vol">10</span>:1155–62.</span> [<a href="/pubmed/11371508" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11371508</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.pollard.2009.250">Pollard JM, Reboucas JS, Durazo A, Kos I, Fike F, Panni M, Gralla EB, Valentine JS, Batinic-Haberle I, Gatti RA. Radioprotective effects of manganese-containing superoxide dismutase mimics on ataxia-telangiectasia cells. <span><span class="ref-journal">Free Radic Biol Med. </span>2009;<span class="ref-vol">47</span>:250–60.</span> [<a href="/pmc/articles/PMC3592562/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3592562</span></a>] [<a href="/pubmed/19389472" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19389472</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.pylk_s.2007.1040">Pylk&#x000e4;s K, Tommiska J, Syrj&#x000e4;koski K, Kere J, Gatei M, Waddell N, Allinen M, Karppinen SM, Rapakko K, K&#x000e4;&#x000e4;ri&#x000e4;inen H, Aittom&#x000e4;ki K, Blomqvist C, Mustonen A, Holli K, Khanna KK, Kallioniemi OP, Nevanlinna H, Winqvist R. Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer. <span><span class="ref-journal">Carcinogenesis. </span>2007;<span class="ref-vol">28</span>:1040–5.</span> [<a href="/pubmed/17166884" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17166884</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.regueiro.2000.177">Regueiro JR, Porras O, Lavin M, Gatti RA. Ataxia-telangiectasia: a primary immunodeficiency revisited. <span><span class="ref-journal">Immunology &#x00026; Allergy Clinics. </span>2000;<span class="ref-vol">20</span>:177–206.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.renwick.2006.873">Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D. Breast Cancer Susceptibiltiy Collaboration (UK), Easton DF, Stratton MR, Rahman N. ATM mutations that cause ataxia-telangiectasia are breast cancer suceptibiltity alleles. <span><span class="ref-journal">Nat Genet. </span>2006;<span class="ref-vol">38</span>:873–5.</span> [<a href="/pubmed/16832357" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16832357</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.sahama.2014a.1289">Sahama I, Sinclair K, Fiori S, Pannek K, Lavin M, Rose S. Altered corticomotor-cerebellar integrity in young ataxia telangiectasia patients. <span><span class="ref-journal">Mov Disord. </span>2014a;<span class="ref-vol">29</span>:1289–98.</span> [<a href="/pubmed/25042086" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25042086</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.sahama.2014b.521">Sahama I, Sinclair K, Pannek K, Lavin M, Rose S. Radiological imaging in ataxia telangiectasia: a review. <span><span class="ref-journal">Cerebellum. </span>2014b;<span class="ref-vol">13</span>:521–30.</span> [<a href="/pubmed/24683014" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24683014</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.sanal.1999.326">Sanal O, Ersoy F, Yel L, Tezcan I, Metin A, Ozyurek H, Gariboglu S, Fikrig S, Berkel AI, Rijkers GT, Zegers BJ. Impaired IgG antibody production to pneumococcal polysaccharides in patients with ataxia-telangiectasia. <span><span class="ref-journal">J Clin Immunol. </span>1999;<span class="ref-vol">19</span>:326–34.</span> [<a href="/pubmed/10535610" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10535610</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.sardanelli.1995.77">Sardanelli F, Parodi RC, Ottonello C, Renzetti P, Saitta S, Lignana E, Mancardi GL. Cranial MRI in ataxia-telangiectasia. <span><span class="ref-journal">Neuroradiology. </span>1995;<span class="ref-vol">37</span>:77–82.</span> [<a href="/pubmed/7708196" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7708196</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.saunderspullman.2012.649">Saunders-Pullman R, Raymond D, Stoessl AJ, Hobson D, Nakamura K, Pullman S, Lefton D, Okun MS, Uitti R, Sachdev R, Stanley K, San Luciano M, Hagenah J, Gatti R, Ozelius LJ, Bressman SB. Variant ataxia-telangiectasia presenting as primary-appearing dystonia in Canadian Mennonites. <span><span class="ref-journal">Neurology. </span>2012;<span class="ref-vol">78</span>:649–57.</span> [<a href="/pmc/articles/PMC3286230/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3286230</span></a>] [<a href="/pubmed/22345219" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22345219</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.saunderspullman.2009.414">Saunders-Pullman RJ, Gatti R. Ataxia-telangiectasia: without ataxia or telangiectasia? <span><span class="ref-journal">Neurology. </span>2009;<span class="ref-vol">73</span>:414–5.</span> [<a href="/pubmed/19605768" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19605768</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.saviozzi.2002.57">Saviozzi S, Saluto A, Taylor AM, Last JI, Trebini F, Paradiso MC, Grosso E, Funaro A, Ponzio G, Migone N, Brusco A. A late onset variant of ataxia-telangiectasia with a compound heterozygous genotype, A8030G/7481insA. <span><span class="ref-journal">J Med Genet. </span>2002;<span class="ref-vol">39</span>:57–61.</span> [<a href="/pmc/articles/PMC1734960/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1734960</span></a>] [<a href="/pubmed/11826028" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11826028</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.sch_tte.2016.143">Sch&#x000fc;tte P, M&#x000f6;ricke A, Zimmermann M, Bleckmann K, Reism&#x000fc;ller B, Attarbaschi A, Mann G, Bodmer N, Niggli F, Schrappe M, Stanulla M, Kratz CP. Preexisting conditions in pediatric ALL patients: Spectrum, frequency and clinical impact. <span><span class="ref-journal">Eur J Med Genet. </span>2016;<span class="ref-vol">59</span>:143–51.</span> [<a href="/pubmed/26732628" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26732628</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.scott.2002.925">Scott SP, Bendix R, Chen P, Clark R, Dork T, Lavin MF. Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2002;<span class="ref-vol">99</span>:925–30.</span> [<a href="/pmc/articles/PMC117407/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC117407</span></a>] [<a href="/pubmed/11805335" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11805335</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.shaikh.2013.2728">Shaikh AG, Marti S, Tarnutzer AA, Palla A, Crawford TO, Zee DS, Straumann D. Effects of 4-aminopyridine on nystagmus and vestibule-ocular reflex in ataxia-telangiectasia. <span><span class="ref-journal">J. Neurol. </span>2013;<span class="ref-vol">260</span>:2728–35.</span> [<a href="/pubmed/23884713" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23884713</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.shen.2010.245">Shen J, Gilmore EC, Marshall CA, Haddadin M, Reynolds JJ, Eyaid W, Bodeli A, Allen K, Chang BS, Grix A, Shill RS, Tocu M, Caldecott RW, Barkovich AJ, Walsh CA. Mutations in PNKP cause microcephaly, seizures and defects in DNA repair. <span><span class="ref-journal">Nat Genet. </span>2010;<span class="ref-vol">42</span>:245–9.</span> [<a href="/pmc/articles/PMC2835984/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2835984</span></a>] [<a href="/pubmed/20118933" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20118933</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.spring.2002.185">Spring K, Ahangari F, Scott SP, Waring P, Purdie DM, Chen PC, Hourigan K, Ramsay J, McKinnon PJ, Swift M, Lavin MF. Mice heterozygous for mutation in Atm, the gene involved in ataxia- telangiectasia, have heightened susceptibility to cancer. <span><span class="ref-journal">Nat Genet. </span>2002;<span class="ref-vol">32</span>:185–90.</span> [<a href="/pubmed/12195425" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12195425</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.stankovic.1998.334">Stankovic T, Kidd AM, Sutcliffe A, McGuire GM, Robinson P, Weber P, Bedenham T, Bradwell AR, Easton DF, Lennox GG, Haites N, Byrd PJ, Taylor AM. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. <span><span class="ref-journal">Am J Hum Genet. </span>1998;<span class="ref-vol">62</span>:334–45.</span> [<a href="/pmc/articles/PMC1376883/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1376883</span></a>] [<a href="/pubmed/9463314" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9463314</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.staples.2008.214">Staples ER, McDermott ERM, Reiman A, Byrd PJ, Ritchie S, Taylor AMR, Davies EG. Immunodeficiency in ataxia telangiectasia is correlated strongly with the presence of two null mutations in the ataxia telangiectasia mutated gene. <span><span class="ref-journal">Clin Exp Immunol. </span>2008;<span class="ref-vol">153</span>:214–20.</span> [<a href="/pmc/articles/PMC2492895/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2492895</span></a>] [<a href="/pubmed/18505428" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18505428</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.stewart.2001.30133">Stewart GS, Last JI, Stankovic T, Haites N, Kidd AM, Byrd PJ, Taylor AM. Residual ataxia telangiectasia mutated protein function in cells from ataxia telangiectasia patients, with 5762ins137 and 7271T--&#x0003e;G mutations, showing a less severe phenotype. <span><span class="ref-journal">J Biol Chem. </span>2001;<span class="ref-vol">276</span>:30133–41.</span> [<a href="/pubmed/11382771" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11382771</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.stewart.1999.577">Stewart GS, Maser RS, Stankovic T, Bressan DA, Kaplan MI, Jaspers NG, Raams A, Byrd PJ, Petrini JH, Taylor AM. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. <span><span class="ref-journal">Cell. </span>1999;<span class="ref-vol">99</span>:577–87.</span> [<a href="/pubmed/10612394" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10612394</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.stewart.2009.420">Stewart GS, Panier S, Townsend K, Al-Hakim AK, Kolas NK, Miller ES, Nakada S, Ylanko J, Olivarius S, Mendez M, Oldreive C, Wildenhain J, Tagliaferro A, Pelletier L, Taubenheim N, Durandy A, Byrd PJ, Stankovic T, Taylor AM, Durocher D. The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damage. <span><span class="ref-journal">Cell. </span>2009;<span class="ref-vol">136</span>:420–34.</span> [<a href="/pubmed/19203578" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19203578</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.stilgenbauer.2000.127">Stilgenbauer S, Schaffner C, Winkler D, Ott G, Leupolt E, Bentz M, Moller P, Muller-Hermelink HK, James MR, Lichter P, Dohner H. The ATM gene in the pathogenesis of mantle-cell lymphoma. <span><span class="ref-journal">Ann Oncol. </span>2000;<span class="ref-vol">11</span> Suppl 1:127–30.</span> [<a href="/pubmed/10707794" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10707794</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.sun.2002.724">Sun X, Becker-Catania SG, Chun HH, Hwang MJ, Huo Y, Wang Z, Mitui M, Sanal O, Chessa L, Crandall B, Gatti RA. Early diagnosis of ataxia-telangiectasia using radiosensitivity testing. <span><span class="ref-journal">J Pediatr. </span>2002;<span class="ref-vol">140</span>:724–31.</span> [<a href="/pubmed/12072877" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12072877</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.sutton.2004.891">Sutton IJ, Last JIK, Richie SJ, Harrington HJ, Byrd PH, Taylor AMR. Adult-onset ataxia telangiectasia due to ATM 5762ins137 mutation homozygosity. <span><span class="ref-journal">Ann Neurol. </span>2004;<span class="ref-vol">55</span>:891–5.</span> [<a href="/pubmed/15174027" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15174027</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.swift.1991.1831">Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. <span><span class="ref-journal">N Engl J Med. </span>1991;<span class="ref-vol">325</span>:1831–6.</span> [<a href="/pubmed/1961222" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1961222</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.tangsinmankong.2001.939">Tangsinmankong N, Wayne AS, Howenstine MS, Washington KR, Langston C, Gatti RA, Good RA, Nelson RP Jr. Lymphocytic interstitial pneumonitis, elevated IgM concentration, and hepatosplenomegaly in ataxia-telangiectasia. <span><span class="ref-journal">J Pediatr. </span>2001;<span class="ref-vol">138</span>:939–41.</span> [<a href="/pubmed/11391347" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11391347</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.tavani.2003.315">Tavani F, Zimmerman RA, Gerry GT, Sullivan K, Gatti R, Bingham P. Ataxia-telangiectasia: the pattern of cerebellar atrophy on MRI. <span><span class="ref-journal">Neuroradiology. </span>2003;<span class="ref-vol">45</span>:315–9.</span> [<a href="/pubmed/12740724" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12740724</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.tavtigian.2009.427">Tavtigian SV, Oefner PJ, Babikyan D, Hartmann A, Healey S, Le Calvez-Kelm F, Lesueur F, Byrnes GB, Chuang SC, Forey N, Feuchtinger C, Gioia L, Hall J, Hashibe M, Herte B, McKay-Chopin S, Thomas A, Vall&#x000e9;e MP, Voegele C, Webb PM, Whiteman DC. Australian Cancer Study; Breast Cancer Family Registries (BCFR); Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab), Sangrajrang S, Hopper JL, Southey MC, Andrulis IL, John EM, Chenevix-Trench G. Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. <span><span class="ref-journal">Am J Hum Genet. </span>2009;<span class="ref-vol">85</span>:427–46.</span> [<a href="/pmc/articles/PMC2756555/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2756555</span></a>] [<a href="/pubmed/19781682" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19781682</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.taylor.2005.1009">Taylor AM, Byrd PJ. Molecular pathology of ataxia telangiectasia. <span><span class="ref-journal">J Clin Pathol. </span>2005;<span class="ref-vol">58</span>:1009–15.</span> [<a href="/pmc/articles/PMC1770730/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1770730</span></a>] [<a href="/pubmed/16189143" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16189143</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.telatar.1998.36">Telatar M, Castellvi-Bel S, Tai L-Q, Wang Z, Regueiro JR, Porras O, Gatti RA. A model for ATM heterozygote identificiation in a large population: Four founder effect ATM mutations identify most of Costa Rican patients with ataxia-telangiectasia:. <span><span class="ref-journal">Molec Genet Metab. </span>1998;<span class="ref-vol">64</span>:36–43.</span> [<a href="/pubmed/9682216" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9682216</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.van_egmond.2015.726">van Egmond ME, Elting JW, Kuiper A, Zutt R, Heineman KR, Brouwer OF, Sival DA, Willemsen MA, Tijssen MA, de Koning TJ. Myoclonus in childhood-onset neurogenetic disorders: The importance of early identification and treatment. <span><span class="ref-journal">Eur J Paediatr Neurol. </span>2015;<span class="ref-vol">19</span>:726–9.</span> [<a href="/pubmed/26232052" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26232052</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.van_os.2016.105">van Os NJ, Roeleveld N, Weemaes CM, Jongmans MC, Janssens GO, Taylor AM, Hoogerbrugge N, Willemsen MA. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. <span><span class="ref-journal">Clin Genet. </span>2016;<span class="ref-vol">90</span>:105–17.</span> [<a href="/pubmed/26662178" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26662178</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.verhagen.2009.430">Verhagen MM, Abdo WF, Willemsen MA, Hogervorst FB, Smeets DF, Hiel JA, Brunt ER, van Rijn MA, Majoor Krakauer D, Oldenburg RA, Broeks A, Last JI, van't Veer LJ, Tijssen MA, Dubois AM, Kremer HP, Weemaes CM, Taylor AM, van Deuren M. Clinical spectrum of ataxia-telangiectasia in adulthood. <span><span class="ref-journal">Neurology. </span>2009;<span class="ref-vol">73</span>:430–37.</span> [<a href="/pubmed/19535770" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19535770</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.verhagen.2012.561">Verhagen MM, Last JI, Hogervorst FBL, Smeets DFCM, Roeleveld N, Verheijen F, Catsman-Berrevoets CE, Wulffraat NM, Cobben JM, Hiel J, Brunt ER, Peeters EA, G&#x000f3;mez Garcia EB, van der Knaap MS, Lincke CR, Laan LA, Tijssen MA, van Rijn MA, Majoor-Krakauer D, Visser M, van 't Veer LJ, Kleijer WJ, van de Warrenburg BP, Warris A, de Groot IJ, de Groot R, Broeks A, Preijers F, Kremer BH, Weemaes CM, Taylor MA, van Deuren M, Willemsen MA. Presence of ATM protein and residual kinase activity correlates with the phenotype in ataxia-telangiectasia: A genotype-phenotype study. <span><span class="ref-journal">Hum Mutat. </span>2012;<span class="ref-vol">33</span>:561–71.</span> [<a href="/pubmed/22213089" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22213089</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.voss.2014.123">Voss S, Pietzner J, Hoche F, Taylor AMR, Last JI, Schubert R, Zielen S. Growth retardation and growth hormone deficiency in patients with ataxia telangiectasia. <span><span class="ref-journal">Growth Factors. </span>2014;<span class="ref-vol">32</span>:123–9.</span> [<a href="/pubmed/25060036" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25060036</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.wallis.2007.79">Wallis LI, Griffiths PD, Ritchie SJ, Romanowski CA, Darwent G, Wilkinson ID. Proton spectroscopy and imaging at 3T in ataxia-telangiectasia. <span><span class="ref-journal">AJNR Am J Neuroradiol. </span>2007;<span class="ref-vol">28</span>:79–83.</span> [<a href="/pubmed/17213429" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17213429</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.waltes.2009.605">Waltes R, Kalb R, Gatei M, Kijas AW, Stumm M, Sobeck A, Wieland B, Varon R, Lerenthal Y, Lavin MF, Schindler D, D&#x000f6;rk T. Human RAD50 deficiency in a Nijmegen breakage syndrome-like disorder. <span><span class="ref-journal">Am J Hum Genet. </span>2009;<span class="ref-vol">84</span>:605–16.</span> [<a href="/pmc/articles/PMC2681000/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2681000</span></a>] [<a href="/pubmed/19409520" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19409520</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.welch.2007.87">Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen G, Jones S, Ren H, Moon YC, Corson D, Turpoff AA, Campbell JA, Conn MM, Khan A, Almstead NG, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, Branstrom AA, Colacino JM, Babiak J, Ju WD, Hirawat S, Northcutt VJ, Miller LL, Spatrick P, He F, Kawana M, Feng H, Jacobson A, Peltz SW, Sweeney HL. PTC124 targets genetic disorders caused by nonsense mutations. <span><span class="ref-journal">Nature. </span>2007;<span class="ref-vol">447</span>:87–91.</span> [<a href="/pubmed/17450125" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17450125</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.williams.2016.1">Williams JR, Trias E, Beilby PR, Lopez NI, Labut EM, Bradford CS, Roberts BR, McAllum EJ, Crouch PJ, Rhoads TW, Pereira C, Son M, Elliott JL, Franco MC, Est&#x000e9;vez AG, Barbeito L, Beckman JS. Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SOD(G93A) mice co-expressing the Copper-Chaperone-for-SOD. <span><span class="ref-journal">Neurobiol Dis. </span>2016;<span class="ref-vol">89</span>:1–9.</span> [<a href="/pmc/articles/PMC4785045/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4785045</span></a>] [<a href="/pubmed/26826269" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26826269</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.wilschanski.2003.1433">Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah-Abram T, Bebok Z, Shushi L, Kerem B, Kerem E. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. <span><span class="ref-journal">N Engl J Med. </span>2003;<span class="ref-vol">349</span>:1433–41.</span> [<a href="/pubmed/14534336" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14534336</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.woods.1992.169">Woods CG, Taylor AM. Ataxia telangiectasia in the British Isles: the clinical and laboratory features of 70 affected individuals. <span><span class="ref-journal">Q J Med. </span>1992;<span class="ref-vol">82</span>:169–79.</span> [<a href="/pubmed/1377828" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1377828</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.yakusheva.2007.973">Yakusheva TA, Shaikh AG, Green AM, Blazquez PM, Dickman JD, Angelaki DE. Purkinje cells in posterior cerebellar vermis encode motion in an inertial reference frame. <span><span class="ref-journal">Neuron. </span>2007;<span class="ref-vol">54</span>:973–85.</span> [<a href="/pubmed/17582336" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17582336</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.yanofsky.2009.462">Yanofsky RA, Seshia SS, Dawson AJ, Stobart K, Greenberg CR, Booth FA, Prasad C, Del Bigio MR, Wrogemann JJ, Fike F, Gatti RA. Ataxia-telangiectasia: atypical presentation and toxicity of cancer treatment. <span><span class="ref-journal">Can J Neurol Sci. </span>2009;<span class="ref-vol">36</span>:462–7.</span> [<a href="/pubmed/19650357" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19650357</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ataxia-telangiectas.REF.zhang.2009.2046">Zhang Q, Davis JC, Lamborn IT, Freeman AF, Jing H, Favreau AJ, Matthews HF, Davis J, Turner ML, Uzel G, Holland SM, Su HC. Combined immunodeficiency associated with DOCK8 mutations. <span><span class="ref-journal">N Engl J Med. </span>2009;<span class="ref-vol">361</span>:2046–55.</span> [<a href="/pmc/articles/PMC2965730/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2965730</span></a>] [<a href="/pubmed/19776401" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19776401</span></a>]</div></li></ul></div></div><div id="ataxia-telangiectas.Chapter_Notes"><h2 id="_ataxia-telangiectas_Chapter_Notes_">Chapter Notes</h2><div id="ataxia-telangiectas.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>27 October 2016 (bp) Comprehensive update posted live</div></li><li class="half_rhythm"><div>11 March 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 February 2005 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>10 April 2003 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> available</div></li><li class="half_rhythm"><div>8 October 2002 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 March 1999 (pb) Review posted live</div></li><li class="half_rhythm"><div>13 April 1998 (rg) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK26468</span><span class="label">PMID: <a href="/pubmed/20301790" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301790</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/aved/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ao2/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK26468&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK26468/?report=reader">PubReader</a></li><li><a href="/books/NBK26468/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK26468" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK26468" style="display:none" title="Cite this Page"><div class="bk_tt">Gatti R, Perlman S. Ataxia-Telangiectasia. 1999 Mar 19 [Updated 2016 Oct 27]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK26468/pdf/Bookshelf_NBK26468.pdf">PDF version of this page</a> (516K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#ataxia-telangiectas.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#ataxia-telangiectas.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#ataxia-telangiectas.Clinical_Characteris" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#ataxia-telangiectas.GeneticallyRelated_A" ref="log$=inpage&amp;link_id=inpage">Genetically-Related (Allelic) Disorders</a></li><li><a href="#ataxia-telangiectas.Differential_Diagnos" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#ataxia-telangiectas.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#ataxia-telangiectas.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#ataxia-telangiectas.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#ataxia-telangiectas.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#ataxia-telangiectas.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#ataxia-telangiectas.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=472[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ATM</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1500074" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1500074" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1500074" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1500074" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301355" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Nijmegen Breakage Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Nijmegen Breakage Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Varon R, Demuth I, Chrzanowska KH. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301294" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Brashear A, Sweadner KJ, Cook JF, Swoboda KJ, Ozelius L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28541650" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> SLC39A14 Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> SLC39A14 Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Tuschl K, Gregory A, Meyer E, Clayton PT, Hayflick SJ, Mills PB, Kurian MA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28933809" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Isolated Sulfite Oxidase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Isolated Sulfite Oxidase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bindu PS, Nagappa M, Bharath RD, Taly AB. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27884168" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ataxia telangiectasia: a review.</a><span class="source">[Orphanet J Rare Dis. 2016]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ataxia telangiectasia: a review.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Rothblum-Oviatt C, Wright J, Lefton-Greif MA, McGrath-Morrow SA, Crawford TO, Lederman HM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Orphanet J Rare Dis. 2016 Nov 25; 11(1):159. Epub 2016 Nov 25.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301790" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301790" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04142add21425a25d54e43">Ataxia-Telangiectasia - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Ataxia-Telangiectasia - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:00:11-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8C10B2E0407CB100000000052901E0&amp;ncbi_session=CE8C10B2E04142A1_1321SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK26468%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK26468&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK26468/&amp;ncbi_pagename=Ataxia-Telangiectasia - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C10B2E04142A1_1321SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>